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DEVELOPMENT OF HYPOXIA TRAPPING ENHANCED BB2R-TARGETED RADIOPHARMACEUTICS
FOR PROSTATE CANCER
Zhengyuan Zhou, Ph.D.
University of Nebraska, 2015

Supervisor: Jered C. Garrison, Ph.D.
ABSTRACT
The Gastrin-Releasing Peptide Receptor (BB2r) has been investigated as a diagnostic and
therapeutic target for prostate and other cancers due to the high expression level on neoplastic
relative to normal tissues. A variety of BB2r-targeted agents have been developed utilizing the
bombesin(BBN) peptide, which has shown nanomolar binding affinity to human BB2r. However,
as with most of the low-molecular weight, receptor-targeted drugs, a major challenge to clinical
translation of BB2r-targeted agents is the low retention at the tumor site due to intrinsically
high diffusion and efflux rates. Our laboratory seeks to address this deficiency by developing
synthetic approaches to selectively increase retention of BB2r-targeted agents in prostate
cancer. Hypoxic regions commonly exist in prostate tumors and many other cancers due to a
chaotic vascular architecture which impedes delivery of oxygen. In this dissertation, we explore
the incorporation of nitroimidazoles, a hypoxia-selective prodrug which irreversibly binds to
intracellular nucleophiles in hypoxic tissues, into the BB2r-targeted agent paradigm. We seek to
determine if these agents can increase the long-term retention in the tumor and thereby
increase efficacy and clinical potential of BB2r-targeted agents.
To that end, we have developed several generations of hypoxia trapping enhanced BBN analogs.
Our first in vitro investigation of hypoxia-enhanced 111In-labeled BBN conjugates demonstrated
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significantly improved retention in hypoxic PC-3 human prostate cancer cells. However, it was
determined that the proximity of the 2-nitroimidazole relative to the pharmacophore had a
detrimental impact on BB2r binding affinity. To address the problem, our next generation of
radioconjugates contained an extended linker to eliminate steric inhibition. The new design
demonstrated substantially improved binding affinity and lower clearance rate of the 2nitroimidazole containing radioconjugates under hypoxic conditions. In vivo biodistribution
studies using a PC-3 xenograft mouse model revealed significant tumor retention enhancement.
Further work is needed to clarify the mechanisms of cellular retention and to correlate the
tumor hypoxia burden with the retention efficacy.
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Chapter 1 INTRODUCTION: RADIOLABELED BOMBESIN ANALOGS FOR PROSTATE CANCER
IMAGING
1.1 INTRODUCTION
The gastrin releasing peptide receptor (GRPr), also known as BB2 receptor (BB2r), has
widespread distribution in the central nervous system (CNS) and gastrointestinal (GI) tract and
mediates a variety of biological activities including modulation of memory [1], emotional arousal
[2], stimulation of gastrin release and pancreatic secretion [3]. During the past 30 years, the
BB2r has drawn great attention as a diagnostic and/or therapeutic target due to its
overexpression in various cancers such as pancreatic, glioblastoma, prostate (PCa), breast,
colorectal, and small-cell lung (SCLC). The growth of tumors and development of metastases
depends on angiogenesis. The activation of overexpressed BB2r has been demonstrated to
trans-activate epidermal growth factor receptor (EGFR) and induce mitogen-activated protein
kinase (MAPK) phosphorylation, which results in proliferation of cancer cells [4, 5]. For both
colon and prostate cancer, the BB2r activation can also up-regulate intracellular adhesion
molecule (ICAM)-1 and stimulate focal adhesion kinase (FAK) thus facilitating cell attachment to
extracellular matrix and promoting cell motility [6]. To date, overexpression of BB2r has been
reported in 85 to 100% of SCLC, 38 to 72% of breast cancer, 72 to 85% of glioblastoma and 62 to
100% of prostate cancer samples [7]. These findings have given the impetus for the
development of targeted theranostic agents for BB2r-positive cancers.
In 1989, peptide-based radiopharmaceuticals were first introduced into the clinic for
localization of endocrine-related tumors using radioiodinated somatostatin analogs [8]. FDAapproved receptor-targeted radiopeptide
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In-DTPA0-octreotide (OctreoScan) has been widely

used for initial staging or re-evaluation of patients with neuroendocrine tumors. Due to their
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small size and hydrophilic nature, radiolabeled peptides usually exhibit favorable
pharmacokinetics including fast targeting, rapid plasma clearance and deep tumor penetrating
properties. To date, a variety of radionuclides, such as 18F, 99mTc, 111In, 188Re, 90Y, 64Cu, 177Lu, 44Sc
and 68Ga, have been used in the design of diagnostic and therapeutic BB2r-targeted agents [917]. For those radioconjugates utilizing a radiometal, bifunctional chelating agents are used to
obtain in vivo stable complexes. The bifunctional chelate design consists of four components: a
radioisotope, a chelator, a linker and a targeting vector. To connect the chelated radioisotope
and the targeting vector, the linker is introduced to not only prevent the radiometal-chelator
complex from sterically inhibiting the binding affinity of the targeting vector, but also plays an
important role in altering the hydrophilicity and optimizing the biodistribution characteristics of
the radioconjugate. Amino acids, aromatic derivatives, aliphatic hydrocarbons, and polyethylene
glycol (PEG) are the most utilized linking chemistries for BB2r-targeted agents. Bombesin (BN), a
14 amino acid amphibian peptide, shares the C-terminal binding sequence (Trp-Ala-Val-Gly-HisLeu-Met-NH2) with the Gastrin Releasing Peptide (GRP, endogenous ligand of BB2r). It has been
shown that these seven amino acids are responsible for the nanomolar BB2r-binding affinity for
both BN and GRP (Figure 1.1). A diversity of BN- and GRP-like peptides (entire, truncated or
modified) have been utilized for development of BB2r-targeted analogs [13, 18, 19]. To date, BN
(7-14)NH2 analogs have been the most frequently investigated BN agonist. Agonists not only
bind to the receptor, but also activate the receptor to induce internalization thereby enhancing
residence time in the BB2r-positive cell/tissue. Until recently, most BN radiotracers utilized for
molecular imaging and therapy have mainly been agonists due to the belief that the
internalization process provides higher tumor accumulation. However, recent findings suggest
that some BN antagonists, which internalize poorly into BB2r-positive tissues, have superior in
vivo tumor uptake and, surprisingly, substantially better retention relative to most, if not all,
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reported agonists [20]. While the mechanism of BN antagonist retention is not yet fully
understood, it is clear, based on the number of literature reports, that researchers have been
devoting substantially more effort in the last few years to develop BN antagonists, which
typically exhibit higher metabolic stability and low receptor dissociation rates [20-22].
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Figure 1.1 Chemical structure of Gastrin-releasing peptide and bombesin peptide
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An ideal peptide based radiotracer is characterized by rapid and specific targeting capability,
high binding affinity, high metabolic stability and high target-to-background ratios. To meet
these chemical, biological and pharmacokinetic characteristics; structure-activity investigations
are often carried out to optimize binding affinity, stability, hydrophilicity, tumor uptake and
retention and non-target tissue clearance. In this review, we focus on summarizing the literature
of the past five year, particularly those studies that shed light on the structure-activity
relationships that pertain to metabolic stability, N-terminal charges, and hydrophilicity. We also
discuss multimerization/hybrid design and summarize results from clinical studies of BN
agonist/antagonist that have been reported in the past five years.
1.2 METABOLIC STABILITY
Based on in vitro studies, BN analogs usually exhibit good human serum stability considering
its fast targeting pharmacokinetics. However, it has been recently found that metabolism
kinetics determined from in vitro serum studies of a radiolabeled peptide have poor correlation
with the in vitro human blood stability or in vivo stability results [21, 23]. A recent clinical study
conducted by Ananias et al. using

99m

Technetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14)NH2

(99mTc-HABBN) failed to detect prostate cancer lesions in patients; this was mainly attributed to
the unexpected low in vivo stability [24]. Less than 20% of the administered peptide was intact
after 30 min, which is significantly lower than the in vitro human serum stability results (77%
intact peptide after 24 h incubation). These findings strongly suggest the need to develop BN
analogs with higher metabolic stability for successful clinical translation.
Replacement of L-amino acid with un-natural or modified amino acid has been a widely used
strategy to prevent the proteolytic cleavage of radiolabeled peptides [25]. Recently,
Marsouvanidis et al. reported the synthesis and comparative evaluation of five single-Gly24 or
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double-Gly24/Met27 substituted GRP(18-27) radiotracers [13](Figure 2). Gly24 substitution by dAla
(SARNC2), βAla(SARNC5), or Sar (SARNC6) were designed for higher metabolic stability and
Met27 substitution with either Nle (SARNC3 dAla24/Nle27) or Leu (SARNC4 dAla24/Leu27) were
designed to prevent the formation of methionine sulfoxide which has been proven to
substantially reduce biological activity [26]. In vitro competitive binding studies revealed that
99m

Tc-SARNC5 had the highest binding affinity followed by

SARNC3 and

99m

Tc-SARNC6,

99m

Tc-SARNC4. Unlike the IC50 results, the least competitive

the highest in vivo stability followed by

99m

Tc-SARNC6,

99m

Tc-SARNC2,

99m

Tc-SARNC2,

99m

Tc-

99m

Tc-SARNC4 showed

99m

Tc-SARNC5 and

99m

Tc-

SARNC3. However, in vivo biodistribution studies demonstrated neither the analog with highest
receptor affinity (SARNC5) or metabolic stability (SARNC4) alone lead to the most favorable in
vivo profile. Instead,

99m

Tc-SARNC6, which had both high BB2r affinity and metabolic stability,

exhibited the most desirable in vivo profile in terms of tumor uptake and tumor-to-non-target
tissue ratio (Table 1.1).
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Figure 1.2 Chemical structures of SARNCs
SARNC1-X24/Y27 = Gly24/Met27; SARNC2-dAla24/Met27; SARNC3-dAla24/Nle27;
Ala24/Leu27; SARNC5-βAla24/Met27; and SARNC6-Sar24/Met27

SARNC4-
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Table 1.1 In vitro and in vivo data of SARNC conjugate

SARNC4

SARNC3

SARNC2

SARNC1

0.25 ± 0.02

9.29 ± 3.55

2.96 ± 1.33

2.03 ± 1.06

1.66 ± 0.12

IC50 (nM)

42%

32%

51%

17%

40%

30%

% of intact peptide
(5 min p.i.)

6.96 ± 2.15

6.26 ± 1.17

2.73 ± 0.78

1.81 ± 0.20

6.59 ± 0.90

4.71 ± 1.09

Tumor uptake
(%ID/g at 24 h p.i.)

232.00

156.50

45.50

25.86

164.75

117.75

blood

348.00

208.67

54.60

45.25

164.75

117.75

muscle

4.41

1.28

1.74

1.33

2.29

1.83

kidney

Tumor-to-non-target-tissue ratio
at 24 h p.i.

SARNC5
1.78 ± 0.32

SARNC

SARNC6
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The amide bond in the backbone of peptides is susceptible to protease degradation. Studies
have been designed to replace the trans-amide bond by a 1,2,3-triazole isostere due to their
similar size, planarity, H-bonding capabilities, and dipole moment [27](Figure 1.3). This
replacement has been recently reported to be able to enhance proteolytic stability of
radiolabeled peptides while maintaining receptor binding affinity and cell-internalization
properties. Valverde et al. synthesized a series of 177Lu-DOTA-PEG4-[Nle(14)]BBN(7-14)NH2 based
peptidomimetics with amide to triazole substitutions [28](Table 1.2). In vitro blood serum
studies revealed up to 20-fold higher stability of all backbone-modified radiotracers except for
compound 2 and 10. For compound 3, 4, 6 and 8-10, the triazole substitutions completely ruined
the BB2r binding affinity. Compound 5 and 7 exhibited identical BB2r avidity and internalization
properties relative to the control compound 1, but superior metabolic stability (>3-fold half-life).
In vivo studies using compound 5 confirmed enhancement of high proteolytic stability on
improved tumor uptake. It’s interesting to note that the same strategy failed to apply on BN
antagonist JMV594 (DPhe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2) which resulted in total loss of
BB2r avidity [29]. These data suggest that the binding conformation and/or the binding site of
the BN agonist and antagonist may be different.
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Figure 1.3 Scheme of amide-to-triazole substitutions
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7

6

5

4

3

2

1 (control)

[177Lu]DOTA-PEG4-Gln-Trpy[Tz]Ala-Val-Gly-His-Leu-Nle-NH2

[177Lu]DOTA-PEG4-Gln-Trp-Alay[Tz]Val-Gly-His-Leu-Nle-NH2

[177Lu]DOTA-PEG4-Gln-Trp-Ala-Valy[Tz]Gly-His-Leu-Nle-NH2

[177Lu]DOTA-PEG4-Gln-Trp-Ala-Val-Glyy[Tz]His-Leu-Nle-NH2

[177Lu]DOTA-PEG4-Gln-Trp-Ala-Val-Gly-His y[Tz]Leu-Nle-NH2

[177Lu]DOTA-PEG4-Gln-Trp-Ala-Val-Gly-His-Leu y[Tz]Nle-NH2

[177Lu]DOTA-PEG4-Gln-Trp-Ala-Val-Gly-His-Leu-Nle y[Tz]-H

[177Lu]DOTA-PEG4-Gln-Trp-Ala-Val-Gly-His-Leu-Nle-NH2

14

8

16

25

17

>100

60

6

5

Half-life/h

0.5

n.o.

n.o.

24.5

8.4

28.3

n.o.

0.2

29.1

27.7

% Internalization
after 4 h

n.d.

n.d.

n.d.

5.9 ± 1.8

48.6 ± 11.5

3.1 ± 1.0

n.d.

n.d.

3.0 ± 0.5

2.0 ± 0.6

KD/nM

Table 1.2 Structures and biological properties of compounds 1 –10
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[177Lu]DOTA-PEG4-Glny[Tz]Trp-Ala-Val-Gly-His-Leu-Nle-NH2

5

Structure

9

[177Lu]DOTA-PEG4y[Tz]Gln-Trp-Ala-Val-Gly-His-Leu-Nle-NH2

Compound

10
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It is well known that PEGylation can improve pharmacokinetics and pharmacodynamics of
therapeutic molecules by increasing hydrophilicity and protection from enzymatic degradation
[30]. Däpp et al. developed a PEGylated DOTA-[Cha13,Nle14]BN(7–14)NH2 analogue by
incorporating a 5 kDa PEG molecule to the ɛ-amino group of a β3hLys-βAla-βAla spacer between
the targeting peptide and the DOTA chelator [31](Figure 1.4). Compared to the non-PEGylated
control, the PEGylated analogue exhibited a remarkable increase in protease stability with a 5
fold higher half-life in human plasma. However, the PEGylated analogue showed a significant
lower internalization rate (internalized fraction: 3% versus 30%) and reduced binding affinity (16
nM versus 2 nM) relative to the non-PEGylated analogue. These results agree with, as reported
earlier, not only protecting the targeting vector from enzymatic recognition, the PEGylation can
also jeopardize the binding affinity and kinetics [30, 32]. Nonetheless, the PEGylated analogue
exhibited 2-fold higher tumor uptake which might at least partially be attributed to its higher
enzymatic stability.
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Figure 1.4 Chemical structure of DOTA-Lys-BN and DOTA-PEG5k-Lys-BN analogues
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Besides direct chemical modification on the radiotracer itself, co-injection with a particular
enzyme inhibitor provides an alternative way of reducing the in vivo metabolic rate of
radiolabeled peptides. Neutral endopeptidase (NEP), a membrane-bound zinc-containing
metallopeptidase, is expressed in a wide variety of tissues and cleaves peptides at the amino
side of hydrophobic amino acid [33]. It has been demonstrated that the NEP acts as a tumor
suppressor which can limit the proliferation of malignant pulmonary neuroendocrine cells by
hydrolyzing bombesin-like peptides [34]. Phosphoramidon (PA) is a natural and potent inhibitor
of NEP with Ki value of 2 nM. PA has been widely used to investigate the neuroprotective role of
the NEP in Alzheimer’s disease with regard to the degradation of Aβ peptides [35]. To explore
the potential of PA co-administration to enhance the proteolytic resistance of BN analogs, Nock
et al. co-injected PA with radiolabeled somatostatin, gastrin, and bombesin analogues in a
variety of tumor xenograft mouse models [36]. Surprisingly, the amount of intact radiopeptide
in the mouse circulation after the injection of PA increased from <2% to 86%, 12% to 80%, and <
5% to 70% at 5 min post injection (p.i.). The resulting tumor uptake impressively escalated from
< 1% to 14%, < 4% to 21%, and 2% to > 15% ID/g. Similarly, Marsouvanidis et al. co-injected
[177Lu]DOTA-GRP(13-27) with PA in a PC3 xenograft mouse model [37]. In vivo stability studies
revealed that with PA co-injection 63% of the initial dose in the blood remained intact at 5 min
post-administration, whereas only ~ 30% remained intact without PA co-administration. The coinjection group also exhibited much higher in vivo tumor uptake (4.01% ID/g) than the
radiotracer alone group (1.26% ID/g). Compared to strategies that involve the replacement of
amino acids or the addition of side chains, which often results in lowered binding affinities or
poorer biodistribution profiles, the strategy of co-injection of GRP/BN analogs with an enzyme
inhibitor appears to be an attractive option to increase metabolic stability and in vivo targeting.
As a consequence, the authors find it likely that this approach will gain more attention from
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researchers as it continues to be exploited with GRP/BN analogs and other peptidic radiotracers.
However, the safety of using endopeptidase inhibitors in humans needs to be further evaluated
and scrutinized before investigators rely on this adjuvant as part of formulations for future
clinical translation.
1.3 IMPACT OF N-TERMINAL CHARGES ON BINDING AFFINITY
It has been previously observed that modification of the C-terminal portion of BN/GRP
analogs profoundly impacts biological activity as well as the fact that amidation of the Cterminal end is required to achieve high avidity [38]; whereas the N-terminus of the peptide
pharmacophore can typically be substantially altered to obtain favorable characteristics without
significantly impacting binding affinity. However, one exception to that tenet appears to be Nterminal modifications that alter the charge state of the peptide. Studies have shown, for the
most part, that incorporation of positive charge(s) at the N-terminus often led to analogs with
higher BB2r affinity and increased in vivo tumor uptake [39]. Over the past few years, multiple
reports have demonstrated this principle through utilization of standard and non-standard basic
amino acid groups and use of charge offsets between the selected radioisotope and chelator.
Marsouvanidis et al. designed four

111

In-labeled DOTA-GRP(13–27) [DOTA-Lys-Met-Tyr-

ProArg-Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2] analogs with selected truncation site at
position 13(111In-1), 14(111In-2), 17(111In-3), and 18(111In-4) of the human 27-mer GRP sequence
[18]. 111In-1 contains both basic amino acid Lys13 and Arg17 while 111In-2 and 111In-3 contain only
Arg17, and 111In-4 contains neither of the positively charged amino acids (Figure 1.5). The in vitro
competitive binding studies revealed that the truncation, which reduced the peptide chain
length and reduced the N-terminal charge, had a significant impact on receptor affinity:

111

In-1

(IC50 = 2.3 ± 0.2 nM) > 111In-2 (IC50 = 6.6 ± 0.9 nM) > 111In-3 (IC50 = 19.2 ± 2.9 nM) ≫ 111In-4 (IC50 =

16
112 ± 16 nM). Highly correlated with in vitro results, the

111

In-1, which has the best binding

affinity, showed the highest initial in vivo tumor uptake (7.74 ± 1.93% ID/g at 4 h p.i.) whereas
111

In-4 which has the poorest binding affinity exhibited the lowest tumor uptake (3.54 ± 1.09%

ID/g at 4 h PI). However, the favorable in vivo profile of

111

In-1 is completely compromised by

high kidney uptake (46.02 ± 3.73% ID/g at 4 h PI) and retention (29.00 ± 4.86% ID/g at 24 h PI)
which is 8 to 16-fold higher than other analogs. Based on previous knowledge, the renal
retention of

111

In-1 is at least partially due to the positively charged Lys13 which enhanced the

binding to and re-uptake by the negatively charged, multi-ligand receptor megalin, located in
the renal proximal tubules [40].
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Figure 1.5 Molecular structures of 111In-1 and corresponding sequences of 111In-2, 111In-3, and
111
In-4
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In the bifunctional chelate design of BB2r-targeted analogs, the linking group is utilized not
only to chemically connect the targeting vector and radiometal-chelator complex, but also
serves as a convenient handle to fine tune the hydrophilicity and pharmacokinetics without
structural alterations to the pharmacophore and/or radiometal-chelator complex. To increase
the BB2r binding affinity and tumor uptake, Mansi et al. reported an

111

In/68Ga labeled BN

antagonist RM2 ([D-F5Phe6, Ala11]BN(6-13)OMe) utilizing a positively charged spacer (4-amino-1carboxymethyl-piperidine) [41]. Compared with their previous analog

nat

In-RM1[20], which

conjugated the same peptide but through a neutral glycine-4-aminobenzoyl spacer, the

nat

In-

RM2 showed a 1.5-fold higher binding affinity towards the BB2r (Figure 1.6). However, the
increased affinity did not substantially impact in vivo tumor uptake, little to no enhancement
was observed in terms of tumor-to-non-target tissue ratio. On the contrary, the negatively
charged linkers show a superior in vitro and in vivo profile than positively charged linkers in
some cases. Mu et al. reported a series of

18

F-labeled BN antagonists with different linking

groups [42]. Compared to positively charged Arg-Ava(Arginine-5-aminopentanoic acid) linker,
the negatively charged Ala(SO3H)-Ava((R)2-amino-3-sulfopropanoic acid-5-aminopentanoic acid)
not only improved the binding affinity by 6-fold, but also showed significantly better
biodistribution characteristics in terms of tumor uptake and tumor-to-non-target tissue ratios.
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Figure 1.6 Chemical structures of 111In-RM1 and 111In-RM2
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To introduce an N-terminal positive charge, another option is to use differences in charge
offset between the radiometal and the chelator. Several studies have been published in the past
few years that were designed to investigate the potential of using bifunctional chelators to serve
that purpose. Varasteh et al. synthesized four 68Ga-labeled BN antagonists (D-Phe-Gln-Trp-AlaVal-Gly-His-Sta-Leu-NH2, RM26) with different chelators (NOTA, DOTA, NODAGA, DOTAGA) [43].
The resulting local charge of the Ga3+ complex with the di-anionic NOTA, tri-anionic NODAGA
and DOTA, and tetra-anionic DOTAGA is +1, 0, 0 and − 1, respectively. As predicted, the
positively charged natGa-NOTA-PEG2-RM26 exhibited the highest BB2r binding affinity (2.3 ± 0.2
nM), followed by two neutral analogs natGa-NODAGA-PEG2-RM26(3.0 ± 0.2 nM) and natGa-DOTAPEG2-RM26(2.9 ± 0.2 nM), and the negatively charged

nat

Ga-DOTAGA-PEG2-RM26 gave the

lowest binding affinity (10 ± 0.6 nM). These in vitro BB2r-affinity studies correlated with higher
in vivo tumor uptake and tumor-to-non-target organ ratios (Table 1.3). Similarly, Gourni
reported a study of 68Ga/64Cu-NOTA/NODAGA complex labeled BN antagonist MJ9 (D-Phe-GlnTrp-Ala-Val-Gly-His-Sta-Leu-NH2) [44]. The residual charge of Ga3+ when complexed with dianionic NOTA and tri-anionic NODAGA is +1 and 0, respectively. Correspondingly, the bivalent
Cu2+ forms a neutral (0) and a negative (-1) charge complexed with NOTA and NODAGA. With
the +1 positive charge on the N-terminus,

nat

Ga-NOTA-MJ9 exhibited the highest affinity (0.5 ±

0.1 nM), followed by the two neutral analogs (2.1 ± 0.3 and 1.0 ± 0.1 nM), whereas the
negatively charged natCu-NODAGA-MJ9 gave a 10-fold lower binding affinity (5.3 ± 2.5 nM). This
performance trend extended into preclinical studies with

nat

Ga-NOTA-MJ9 demonstrating

superior in vivo behavior with greater tumor uptake and better tumor-to-non-target organ
ratios relative to the neutral and negatively charged radiometal-chelator systems (Table 1.2).
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MJ9

RM26

RM26

RM26

RM26

68Ga

68Ga

68Ga

68Ga

68Ga

68Ga

Radiometal

NOTA

NODAGA

NOTA

DOTAGA

DOTA

NODAGA

NOTA

Bifunctional
chelator

0

0

+1

-1

0

0

+1

Residue
charge

5.3 ± 2.5

1.0 ± 0.1

2.1 ± 0.3

0.5 ± 0.1

10.0 ± 0.6

2.9 ± 0.3

3.0 ± 0.3

2.3 ± 0.2

IC50 (nM)

3.0 ± 0.2c

7.1 ± 0.7c

16.7 ± 2.0b

23.3 ± 2.0b

3.2 ± 0.2a

4.6 ± 0.2a

3.9 ± 0.7a

5.4 ± 1.0a

Tumor
uptake
(% ID/g)

75 ± 1c

79 ± 2c

19 ± 1.6b

35 ± 6.9b

5.5 ± 1.4a

14 ± 6a

22 ± 7a

25 ± 3a

Blood

150 ± 1c

143 ± 1c

46 ± 23b

90 ± 49b

22 ± 3a

61 ± 10a

102 ± 23a

157 ± 23a

Muscle

5 ± 1c

12 ± 1c

4.7 ± 0.1b

6.5 ± 0.8b

1.1 ± 0.1a

1.8 ± 0.2a

1.5 ± 0.4a

3 ± 1a

Kidney

Table 1.3 In vitro and in vivo data of different radiometal/chelator complex

MJ9
64Cu

-1

Data represent at 24 h p.i.

Tumor-to-non-target tissue ratio

MJ9

NODAGA

c

64Cu

Data represent at 1 h p.i.

b

MJ9
Data represent at 2 h p.i.

Targeting
vector

a
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1.4 INCREASING HYDROPHILICITY FOR IMPROVED NON-TARGET TISSUE CLEARANCE
For both diagnostic and therapeutic agents, high target-to-non-target organ ratios are
needed to ensure appropriate imaging contrast and/or therapeutic index. High BB2r-avidity
usually leads to favorable in vivo tumor uptake of BN/GRP analogs. However, tumor uptake is
only part of the equation when developing a clinically viable agent. Clearance of the tracer from
non-target tissues is equally important. As a consequence, the hydrophilicity of the agent plays a
crucial role in balancing the blood circulation time needed for optimal tumor targeting with the
rapid and efficient clearance from non-target organs. Generally, hydrophilic radiotracers are
preferred due to their rapid washout from the abdominal cavity versus more hydrophobic
radiotracers, which often show high liver uptake resulting in unwanted hepatobiliary clearance.
Correlation of distribution coefficients (logD) and in vivo biodistribution characteristics indicates
that logD values below -1.5 are required to avoid high hepatobiliary uptake [45]. Using the
bifunctional chelate design, the water solubility of the BN/GRP analogs can be easily optimized
by altering the composition of the linking group to include hydrophobic or hydrophilic
constituents.
The impact of different lengths of aliphatic hydrocarbon linkers on pharmacokinetic effects
of BN analogs has been thoroughly investigated previously [46, 47]. Recently, a series of 64CuNO2A-(X)-BN(7-14)NH2 analogs with increasing lengths of aliphatic linkers (X=β-Ala, 5-Ava, 6Ahx, 8-Aoc, 9-Anc) and rigid aromatic linker AMBA were synthesized by Lane et al. [48] (Figure
1.7). Roughly based on the HPLC retention time, the hydrophilicity of these BN analogs are
ranked as follow: β-Ala > AMBA ≈ 5-Ava ≈ 6-Ahx > 8-Aoc > 9-Anc. With identical in vitro binding
affinities to the BB2r, these analogs exhibited different in vivo kinetics which correlated with
their hydrophilicity/hydrophobicity character. Higher hepatobiliary uptake was observed with
increasing hydrophobicity on healthy CF-1 mice at 1 h p.i. Of the tested radioconjugates with
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AMBA, 6-Ahx, 8-Aoc and 9-Anc linkers on a PC-3 tumor bearing mouse model, conjugates with
the shorter and more hydrophilic AMBA linker showed the highest tumor-to-liver ratio followed
by conjugates with the 6-Ahx linker. Conjugates with the most hydrophobic 9-Anc linker showed
unfavorable significant amounts of abdominal accumulation.
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Figure 1.7 Chemical structures of glycine-4-aminobenzoyl, β-Ala, 5-Ava, 6-Ahx, 8-Aoc, and 9Anc linkers
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In recent years, PEGs have been utilized more frequently as a linking group moiety.
Advantageously, PEGs are able to reduce the hepatic uptake of radiotracers due to their
hydrophilic nature [49]. The influence of short PEG spacers of various lengths on BN analogs has
been investigated by Jamous et al. [50]. A series of

177

Lu-labeled BN antagonists utilizing the

JMV594 pharmacophore (MJ[1-4]) with PEG spacers of different lengths (n = 2, 4, 6, 12) were
synthesized and evaluated both in vitro and in vivo. With increasing length of PEG linker, these
conjugates showed slightly increased hydrophilicity (LogD range from -1.95 to -2.22). All
conjugates demonstrated similar BB2r binding affinity with IC50 values ranging from 6.2 to 9.9
nM except for the conjugate with the PEG12 linker which exhibited significant lower binding
affinity (IC50 = 15.0 ± 5.3 nM). These results agree with a previously published study, using a
3500 Da PEG spacer, that showed the flexible long PEG chain might mask the receptor binding
site and subsequently impair the binding affinity [51]. Of the tested conjugates, the conjugate
with PEG6 linker showed the highest clearance rate from pancreas, liver and kidney in PC-3
tumor-bearing mice.
1.5 MULTIMERIZATION
In nature, multimerization of biomolecules, such as DNA-DNA duplex formation and
antibody recognition, are used to increase binding affinity and target specificity. It has been
shown that the multimerization of therapeutic drugs and diagnostic agents are able to achieve
this using two distinct mechanisms, enriching the local drug concentration and cooperative
binding to two or more receptors simultaneously through the polyvalency effect [52, 53]. If the
distance between different targeting ligands does not permit multiple binding events, the
number of ligands in the vicinity of the neighboring binding sites would be correspondingly
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enriched; if the distance between targeting ligands matches the receptors’ density on the cell
surface, the ligands would bind to multiple receptors at the same time. Dimeric and tetrameric
radiolabeled arginine-glycine-aspartic acid (RGD) analogs have been extensively investigated
and proven to be an effective approach to enhance the αvβ3 integrin avidity, tumor uptake and
tumor-to-background ratio [54-57]. From these studies and others, it has been shown that the
linker length and flexibility are the key factors influencing the efficacy of the multimeric design.
In order to bind to more than one receptor, the length of the linker should be able to
accommodate the distance between targets. Therefore, the selection of the linker length should
correlate to the cellular receptor density and the average distance between receptors on the
plasma membrane. Meanwhile, certain rigidity of the linker is required to maintain the optimum
distance but without disturbing the flexible binding of the targeting vectors.
1.5.1 HOMOMULTIMERIZATION
Several papers have been published recently regarding radiolabeled bombesin homodimers
or homomultimers [58-61]. Fournier et al. designed and synthesized two 64Cu-labeled [D-Tyr6,
bAla11, Thi13, Nle14] BBN(6-14)NH2 based homodimers with one or two PEG1 spacers (dimer 1
and 2, figure 1.8)[60]. No significant improvement of binding affinity was observed for both
dimer 1 and 2 compare to the monomer (IC50 value range from 1.76 to 2.51 nM). Using dimer 2
for further in vitro analysis, slower internalization rates and higher retention were found when
compared to the monomer. Unfortunately, high liver (23.11 % ID/g) and kidney (26.37 % ID/g)
uptake were observed for 64Cu-NOTA-dimer 2 which resulted in substantially lower tumor-tokidney/liver ratios than the monomer. According to the author, the large molecular weight of
dimer 2 might be the explanation of the high hepatobiliary excretion and low renal clearance.
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Figure 1.8 Chemical structures of 64Cu/NOTA-dimer 1 and 64Cu/NOTA-dimer 2
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Similarly, Lindner et al. reported a series of DOTA-PEG4-BN(7–14)NH2 (PESIN) based dimers,
tetramers, and octamers using either no additional linker or an additional PEG3 or PEG7 linker
[61]. Contrary to their expectations, especially for the tetramers and octamers with longer PEG
spacers, significantly lower BB2r binding affinity was observed (IC50 range from 149 to 419 nM).
The dimer without an extended PEG linker showed a slightly increased binding affinity over the
monomer control (7.77 versus 19.67 nM). In vivo microPET studies revealed identical
performances for both the dimer and monomer in terms of tumor-to-organ ratios.
1.5.2 HETEROMULTIMERIZATION
Instead of using a homomultimer design and flexible aliphatic hydrocarbons or PEG linkers,
Kroll et al. developed a bombesin heterodimer system with a defined distance between an
agonist and an antagonist [62]. By using a conformationally well-defined azidoproline (Azp)
containing oligoprolines as the backbone, three BN heterodimers were synthesized with
distances between AMBA (agonist) and RM1 (antagonist) of 10(1), 20(2) and 30(3) Å,
respectively (Figure 1.9). In vitro internalization studies revealed more than 50% of analog 2
internalized into the PC3 cells with 10% bound on the cell surface, which is among the highest
total cellular uptake reported. The analysis of microPET/CT data showed 18.2% ID/g tumor
uptake at 4 h post injection and up to 83.5% of initial uptake (15.2% ID/g) still retained after 21
h post injection. This heterodimer design as well as the rigid scaffold with a well-defined
distance might be applicable to various targeting ligands.
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Figure 1.9 Chemical structures of oligoproline-based hybrid BN ligands 1-3

30
Covalently linked ligands for targeting multiple receptors have drawn great interest due to
the fact that many cancer types overexpress not just one, but rather multiple valid molecular
targets concurrently. RGD peptides have drawn great attention due to their ability to specifically
target the αvβ3 integrin, which is highly expressed on the endothelial cells of tumor
neovasculature as well as in many tumor cell types such as prostate, pancreatic and breast
cancer [63]. In the past five years, dual targeting analogs consisting of BN and RGD peptides
have been the most investigated heterodimeric BB2r-targeted systems [14, 15, 64-67].
Stott-Reynolds et al. designed an

111

In/177Lu-labeled RGD-RM2 heterodimeric peptide for

dual receptor targeting of prostate cancer [67]. In vitro competitive binding studies indicated
high BB2r-affinity (≈ 5 nM) of the RGD-RM2 conjugate using the PC3 cell line, while only
moderate αvβ3 integrin receptor binding affinity (≈ 360 nM) was observed when tested on the
αvβ3-expressing human glioblastoma U87-MG cell line. In vivo biodistribution studies revealed
both high initial tumor uptake (average of 7.40 ± 0.53% ID/g at 1 h p.i.) and retention (average
of 4.41 ± 0.91% ID/g at 24 h p.i.) in PC-3 tumor-bearing mice. Pre-injection of cold BN or
cyclicRGD peptides is able to reduce the tumor uptake by ~42% or ~20%, respectively, which
confirmed the dual-targeting efficacy of the designed heterodimeric peptide. It’s interesting to
note from other literature reports of RGD-BN heterodimer designs, the affinity of either the αvβ3
or BB2r is usually substantially reduced [14, 15, 64, 65, 67]. Since dimeric RGD designs normally
possess significantly higher αvβ3 affinity than RGD monomers, the reduced binding affinity of BNRGD heterodimer is possibly due to the steric hindrance of the longer BN peptides.
Prostate-specific membrane antigen (PSMA) is a membrane-bound glycoprotein which is
expressed at low levels in benign prostatic epithelium but highly expressed in prostate tumor
epithelium [68]. This has given the impetus for the development of radiopharmaceuticals
targeting PSMA for both diagnostic and therapeutic purpose for recurrent or metastatic
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prostate cancer lesions [69-73]. Since both BB2r and PSMA are concurrently expressed on a
large fraction of prostate cancer tissues, the potential of dual receptor- targeted radiotracers
has been recently evaluated. The PSMA binding motif Glu-NH-CO-NH-Lys was conjugated to a
previously reported BN agonist BZH3 (D-Tyr6, β-Ala11, Thi13, Nle14] BN(6–14)NH2) through a
PEG2/6-Ahx linking system by Eder et al. [74]. The resulting conjugates demonstrated similar
BB2r binding affinity, compared with the monomeric reference, but 2.3-fold lower PSMA
affinity. In vivo studies on both AR42J (BB2r positive) and LNCaP (PSMA positive) xenograft mice
models show identical biodistribution profiles compared with corresponding monomeric
targeting analogs, which suggests the potential to improve the sensitivity in clinical settings. In a
similar design by Bandari et al., the PSMA-targeted agent DUPA(2-[3-(1,3-dicarboxypropyl)ureido]pentanedioic acid) was conjugated to BN(7-14)NH2[75] through a 5-Ava/6-Ahx linking
system. The resulting hybrid targeting agent showed very good binding affinity to both BB2r
(11.1 ± 0.64 nM) and PSMA (1.16 ± 1.35 nM) expressing cells. However, in vivo microPET/CT
revealed unfavorable high liver, spleen, and small intestine retention which significantly limited
the efficacy of imaging primary and metastatic tumor in the abdominal region. These
researchers intend to pursue an alternative design using a BN antagonist, presumably due to the
better clearance profiles of the antagonistic pharmacophores.
1.6 HYBRID BN ANALOGS
For most of the low-molecular weight, receptor-targeted drugs, one of the major challenges
is low retention at tumor site due to intrinsically high diffusion and efflux rates. After receptor
mediated uptake of radiotracers, a fast washout is often observed which substantially reduces
the theranostic efficacy and the potential for clinical translation. To address this issue, one
possible approach is to enhance the cellular retention time in cancer cells by adding another
targeting agent which can be activated and bound to subcellular proteins or organelles. Santos-
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Cuevas et al. have reported a

99m

Tc-labeled lys3-BN peptide hybrid with nuclear localization

peptide sequence (NLS)-Tat(49-57, H-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2), which is derived
from human immunodeficiency virus type 1 (HIV-1) Tat protein [76]. In vitro studies
demonstrated that addition of Tat(49-57) efficiently delivered radiopharmaceuticals to the
nuclei of both prostate and breast cancer cells. Fischer et al. designed a BN peptide hybrid with
heat shock protein 90(Hsp90) inhibitor [77]. Hsp90 is a ubiquitous protein that is overexpressed
in most cancer cells and plays an important role in cell proliferation and survival [78]. Peptide
sequence “shepherdin” (KHSSGCAFL) has been identified as a potent Hsp90 inhibitor with high
affinity and specificity [79]. When investigating the combination of the extracellular BB2rtargeting peptide and the intracellular Hsp90 protein inhibitor, no increased retention of
radioactivity was observed. A possible explanation is that the Hsp90- targeting peptide lost its
specificity after enzymatic degradation in endosomes/lysosomes.
Our lab has been investigating the potential of utilizing the hypoxic characteristic of prostate
cancer to increase retention time of BB2r-targeted agents [80, 81]. Tissue hypoxia is the result of
an inadequate supply of oxygen. In most solid cancers, hypoxic regions commonly exist due to a
chaotic vascular architecture which impedes delivery of oxygen and other nutrients. A recent
clinical investigation found that 63% (median, n=247) of prostate tumors gave pO2
measurements of less than 1.3 kPa (10 mm Hg, tissues less than this are generally defined as
hypoxic)[82]. The extent of hypoxia in tumors appears to be strongly associated with the
aggressiveness of the tumor phenotype, therapeutic resistance and patient prognosis [83, 84].
Since hypoxia is not present in most normal human tissues, a variety of bioreductive, hypoxiaselective prodrugs have been developed for the purpose of diagnostic and therapeutic
applications for cancer [85-87]. Nitroimidazoles have been used extensively in basic and clinical
investigation as diagnostic imaging agents [88, 89]. In hypoxic environments, nitroimidazoles
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undergo a series of enzymatic reductions, mediated by nitroreductase enzymes, leading to the
formation of strong electrophiles which can irreversibly bind to intracellular nucleophiles
thereby trapping the agent in the hypoxic tissue. In our previously published studies [12], totally
four

111

In-labeled BN(7-14)NH2 analogs were synthesized with increasing number (0-3) of the

hypoxia trapping moiety 2-nitroimidazole incorporated on the linker (111In-HE-1-4, Figure 1.10).
Internalization and efflux studies demonstrated that the clearance rate of the radioconjugates
containing 2-nitroimidazoles was substantially lower, relative to the control, under hypoxic
conditions. Cellular protein binding analysis revealed up to 2 fold higher radioactive signal
associated with macromolecules for 2-nitrimidazole containing conjugates compared with the
control. Significant tumor retention improvement was observed at 72 h post injection for
radioconjugates

111

In-HE-2 and

uptake was retained for

111

111

In-HE-4. Specifically, 6.7% and 21.0% of the initial 1h tumor

In-HE-2 and

111

In-HE-4, whereas only 1.5% left for the control

111

In-

HE-1. Currently, we are working on correlating the hypoxia burden of PC3 xenograft tumors with
the hypoxia trapping efficacy of our radioconjugates.
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Figure 1.10 Hypoxia-enhanced 111 In-BB2r–targeted conjugates
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1.7 RECENT CLINICAL STUDIES
A total of eight clinical studies using BB2r-targeted radiotracer were performed in Europe
during the past five years [24, 90-96]. Out of the eight studies, four radioisotopes (99mTc, 18F,
68

Ga and 64Cu) and six BN analogs, including three antagonists and three agonists, have been

investigated on recurrent glioma patients, prostate cancer patients or healthy men (Table 1.4).
In this review, we focus on the six clinical studies of prostate cancer.
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Agonist/
antagonist

Targeting Peptide
sequence

Table 1.4 Radiolabeled bombesin analogs under clinical evaluation
Disease
13

BZH3

BZH3

2012

2011

2011

Prostate
Cancer

NA

Agonist

Antagonist

Antagonist

Pro-Gln-Arg-Tyr-Gly-AsnGln-Trp-Ala-Val-Gly-HisLeu-Nle- NH2

Gln-Trp-Ala-Val-Gly-HisLeu-Met- NH2

D-Phe-Gln-Trp-Ala-ValGly-His-Sta-Leu- NH2

D-Phe-Gln-Trp-Ala-ValGly-His-Sta-Leu-NH2

Year
11

BAY 86-7548

2013
Prostate
Cancer
Agonist

D-Phe-Gln-Trp-Ala-ValGly-His-Sta-Leu- NH2

Radiotracer
6

BAY 86-7548
2013
Prostate
Cancer

Antagonist

Gln-Trp-Ala-Val-NMeGlyHis-Sta-Leu- NH2

Agonist

HABBN

2014
Prostate
Cancer

Antagonist

[D-Tyr , β-Ala , Thi ,
14
Nle ] BN(6–14) NH2
6
11
13
[D-Tyr , β-Ala , Thi ,
14
Nle ] BN(6–14) NH2

Demobesin 4

2014

Prostate
Cancer

Agonist

AR06

2015

Recurrent
Gliomas
Recurrent
Gliomas

BAY 864367

Ga-DOTA

Radioisotope/
Chelator

PEG2

Linking system

7

15

Number of patients

68

PEG2

8

11 prostate cancer patients
and 3 recurrence prostate
cancer patients

5 healthy men

Ga-DOTA

68

Ga-DOTA

68

68

Ga-DOTA

4-amino-1carboxymethylpip
eridine
4-amino-1carboxymethylpip
eridine
ε-aminocaproic
acid

2 patients at early stage and
6 patients with metastasis

Tc-HYNIC

NA

4 patients at early stage

99m

Tc-N4

PEG4

99m

Cu-CB-TE2A

64

Ala(SO3H)Ala(SO3H)-Ava

5 patients at early stage and
5 patients with radical
prostatectomy
3-Cyano-4[18F]fluorobe
nzoyl
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Ananias et al. evaluated the potential of

99m

Tc-labeled BN(7-14)NH2 agonist-HABBN for

detection of prostate cancer in 8 patients [24]. Unfortunately, due to the poor metabolic
stability, it failed to visualize both primary PCa and metastatic prostate cancer. A rapid
metabolic degradation was observed with less than 20% intact peptide remaining after 30 min
post injection. These findings provide further evidence that the in vivo stability in man does not
correlate with in vitro human serum stability, suggesting the need to develop better protocols
for predicting metabolic stability of peptidic radiotracers in humans.
Instead of using BN(7-14)NH2 which has the oxidation-sensitive methionine at the Cterminus, Nock et al. synthesized 99mTc-labeled BN agonist Demobesin 4 ([99mTc]DB4) which has
methionine substituted by norleucine [97]. Both early stage prostate cancer patients and
patients who have undergone hormone ablation therapy were recruited to evaluate the
diagnostic capability of [99mTc]DB4 [94]. For the two patients who had cancer confined to the
prostate and who have had no previous ablation therapy, [99mTc]DB4 successfully delineated the
primary PCa. However, no [99mTc]DB4 uptake in the prostate gland was found for the six patients
who had androgen ablation treatment. Moreover, the majority of the extensive bone metastatic
disease was not visualized by the [99mTc]DB4. It has been previously shown that hormone
treatment leads to the loss of GRPR expression [98]. Taking all of these studies into
consideration, BB2r-targeted radiopharmaceuticals may only be useful for untreated, earlystage prostate cancer patients.
Encouraged by the superior imaging characteristics of somatostatin receptor antagonists,
increasing number of BB2 receptor antagonists have been developed and tested in both animal
models and human subjects. Two clinical studies of 68Ga-bombesin antagonist BAY 86-7548 were
reported by Roivainen et al. [93] and Kähkönen et al. [92]. Five healthy men were studied first to
investigate the safety, tolerability, metabolism, pharmacokinetics, biodistribution and radiation
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dosimetry of BAY 86-7548. Fast plasma metabolism was observed (19% of total radioactivity in
plasma was identified as intact BAY 86-7548 at 65 min post injection) with three metabolites
being identified. The radioactivity mainly accumulated in the pancreas and liver and was
excreted rapidly through renal clearance. The bladder wall and pancreas absorbed the highest
dose at 0.61 and 0.51 mSv/MBq, respectively. The diagnostic potential of BAY 86-7548 was also
investigated in 14 prostate cancer patients. Sensitivity, specificity and accuracy are widely used
statistics to quantify how good and reliable of a diagnostic test [99]. Sensitivity assesses ability
of a diagnostic test for detecting a positive disease. Specificity evaluates the chance of a
diagnostic test to rule out patients without disease. Accuracy estimates the probability of a
diagnostic test to correctly identify and exclude a given condition. In this study, a promising
result with 88% sensitivity, 81% specificity, and 83% accuracy was found for the detection of
primary PCa. Sensitivity of detecting ten histologically proven lymph node metastases was a
little lower; around 70% of these lesions were detected. According to the authors, the possible
explanations for the lower detection efficacy of metastatic relative to primary lesions might be:
1. reduction of BB2r expression, 2. the partial volume effects [100], or 3. small lesions were
missed because the large intervals of whole-mount axial macrosections (8 mm).
Compared to 68Ga, 18F has superior physical characteristics for PET imaging, such as a lower
positron range and a higher positron yield which lead to higher spatial resolution and sensitivity
[101]. A very recent clinical study using 18F-labeled BN antagonist BAY 864367 has been carried
out by Sah et al. [96]. Ten patients with biopsy proven PCa have been recruited for both BAY
864367 and 18F-Fluorocholine scan. The BAY 864367 displayed accumulation in three out of five
patients with primary PCa and two out of five patients with recurrent PCa. The sensitivity of BAY
864367 is lower than an 18F-Fluorocholine scan, which delineated all suspicious lesions. Inverse
correlation between BB2r expression and the Gleason score has been previously reported [102].
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Compared with BAY 86-7548, the lower detection rate of BAY 865367 could be due to the fact
that patients recruited in this study have higher Gleason scores than patients in Kahkonen et
al.’s study (8.3 vs 3.7).
Copper 64 is another positron emitter which has been used in recent clinical studies for
prostate cancer diagnosis. Compared with 68Ga and 18F, 64Cu has a relatively longer half-life (12.7
h versus 68 min and 110 min) which allows for better clearance of radioactivity from non-target
tissues, which might improve imaging contrast. 64Cu-labeled BN antagonist AR06 was examined
in four newly diagnosed PCa patients (T1c-T2b, Gleason 6-7) by Wieser et al. [95]. Rapid tumor
accumulation was observed along with much slower clearance from other BB2r positive organs
which leads to higher contrast tumor delineation in 3 out of 4 patients at all scanning time
points. However, the ability of this radiotracer to detect metastatic lesions still needs to be
evaluated.
1.8 CONCLUSION
In the past five years, great progress has been made in the field of radiolabeled bombesin
analogs at both the preclinical and clinical level. New issues (e.g., non-correlated in vitro/in vivo
metabolic stability and loss of BB2r expression after hormone ablation) have been discovered.
Previously discovered mechanisms to increase in vivo efficacy (e.g., improved binding affinity
with positive charge on N-terminal and increased non-target tissue clearance with elevated
hydrophilicity) have been further verified. New concepts (e.g., co-injection with enzyme
inhibitor and tumor specific cellular trapping) and new designs (e.g., homodimers and
heterodimers) have been introduced and proven to have great potential for improving the
diagnostic and therapeutic efficacy of BB2r-targeted agents.
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Chapter 2 Development of Hypoxia Enhanced 111In-labeled Bombesin Conjugates: Design,
Synthesis and In Vitro Evaluation in PC-3 Human Prostate Cancer1
2.1 INTRODUCTION
As mentioned in Chapter 1, prostate cancer is among the most hypoxic of cancers found in
the clinic. [103, 104] This state of hypoxia is a result of the often chaotic and poor vascular
organization in the tumor thereby inhibiting the ability of the microvasculature to efficiently
deliver oxygen. [104] This chaotic vascular architecture often leads to a high degree of
oxygenation heterogeneity, with the tumor containing anoxic, hypoxic and normoxic regions,
depending on the distance of the tissue from the nearest vascular vessel. Hypoxia has and
continues to be a major obstacle in the treatment of numerous cancers, including prostate
cancer, due to the increased chemotherapy and radiotherapy resistance of hypoxic tissue.[104,
105] While the average fraction of hypoxic tissue in prostate cancer tumors is not well known, it
is expected that the fraction of hypoxic cells would be significant.[106, 107] Since hypoxia is a
property that is not exhibited in most normal human tissues, several classes of bioreductive
prodrugs (i.e. nitroimidazoles, aromatic N-oxides and quinones) are under development to
exploit the hypoxic nature of tumors for diagnostic and therapeutic applications. One class of
bioreductive hypoxia targeting agents that has undergone extensive basic and clinical
investigation is nitroimidazole. [108-110] In hypoxic environments, this class of agent is
selectively reduced (“triggered”) thereby generating a reactive electrophile that becomes
trapped in the hypoxic cell. In particular, 2-nitroimidazole derivatives have been actively

1

The material presented in this Chapter was previously published: Wagh NK, Zhou Z, Ogbomo SM, Shi W,
Brusnahan SK, Garrison JC. Development of hypoxia enhanced 111In-labeled Bombesin conjugates:
design, synthesis, and in vitro evaluation in PC-3 human prostate cancer. Bioconjug Chem. Mar 21
2012;23(3):527-537
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investigated for the development of hypoxia targeted agents capable of quantitating the
hypoxic burden present in tumors using standard nuclear medicine imaging modalities. [111-115]
The BB2 receptor (BB2r), also known as the Gastrin-Releasing Peptide (GRP) receptor, is a
subtype of the Bombesin receptor family.[116] The BB2r has been thoroughly investigated for
the role the receptor plays in neoplastic tissue transformation and growth [117-119]. From
these studies and subsequent work, it was demonstrated that the BB2r is expressed in
significantly higher densities on a number of human tumors and cancer cell lines, including
prostate cancer tissues, relative to normal tissues [117, 118, 120, 121]. These studies have
provided the impetus for the development of BB2r-targeted agents for both diagnostic imaging
and therapeutic applications. To date, most of these agents have revolved around synthetic
analogs of Bombesin (BBN) - a fourteen amino acid, amphibian peptide that shares a C-terminal
binding region sequence homology (Trp-Ala-Val-Gly-His-Leu-Met-NH2, BBN(7-14)NH2) with GRP
(the native ligand for the BB2r)[122]. Analogs utilizing the BBN(7-14)NH2 sequence are able to
agonistically bind to the BB2r with high (typically nanomolar) affinity and facilitate endocytosis
of the agent into the cell.
For BB2r-targeted drugs, as well as most small molecule based targeted ligands, the
targeted conjugates typically demonstrate maximum tumor accumulation shortly after
administration (~ 15-60 min)[122-124]. Unfortunately, one of the major challenges faced by
many targeted peptides is the significant clearance of the drug relatively quickly (~ 1-4 hrs p.i.),
after peak accumulation in the tumor, thereby reducing the diagnostic or therapeutic efficacy of
the BB2r-targeted agent. In an attempt to increase the effectiveness of BB2r-targeted drugs, we
and others have begun to evaluate various means of increasing the retention of the radiolabeled
drug in prostate cancer tumors [125]. Herein, we report the evaluation of BB2r-targeted agents
that include the use of 2-nitroimidazoles as hypoxia trapping moieties to increase the retention
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of the drug in hypoxic tumor cells. Specifically, we synthesized four BB2r-targeted agents, that
include (0 - 3) 2-nitroimidazole moieties, and evaluated the in vitro binding affinity and
retention efficacy of the radioconjugates in normoxic and hypoxic PC-3 human prostate cancer
cells. The structures of synthesized agents are depicted in Figure 2.1.
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Figure 2.1 Hypoxia enhanced 111In-BB2r-targeted conjugates
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2.2 MATERIALS AND METHODS
2.2.1. Chemicals and Equipment
Unless otherwise noted all solvents were used without further purification. Deionized water
was purified by a Millipore (U.S.) Mili-Q-Biocel. Ethylbromoacetate was purchased from Acros
Organics (U.S.). Silica and TLC plates were purchased from Sorbent Technologies (U.S.).
Acetonitrile, formic acid, N, N-diisopropylethylamine (DIEA), N,N-dimethylformamide (DMF),
dichloromethane (DCM), N,N'-dicyclohexylcarbodiimide (DCC) , N-methylpyrrolidone (NMP),
thioanisol, L-ascorbic acid, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), bovine
serum albumin (BSA) and sodium dodecyl sulfate (SDS) were purchased from Fisher Scientific
(U.S.). 2-nitroimidazole was purchased from Amfinecom (U.S.). O-Benzotriazole-N,N,N’,N’tetramethyl-uronium-hexafluoro-phosphate (HBTU), Fmoc-protected natural amino acids and
the appropriate Rink Amide resins were purchased from Nova Biochem (U.S.). Fmoc-5-AOC and
Fmoc-5-Ava were purchased from CreoSalus (U.S). Phosphate buffered saline (PBS) and
Mammalian Protein Extraction Reagent (M-PER) were purchased from Thermo Scientific (U.S.).
Indium-111 chloride (111InCl3) was purchased from MDS Nordon (Canada). Naturally abundant
indium chloride (natInCl3), triisopropyl silane and 3,6-dioxa-1,8-octanedithiol were purchased
from Sigma-Aldrich (U.S.). The [125I-Tyr4]-Bombesin was purchased from Perkin Elmer (U.S.).
Cation exchange resin was purchased from Bio Rad (USA). Prostate cancer (PC-3) cell lines were
obtained from American Type Culture Collection (U.S.) and cultured under vendor
recommended conditions. Roswell Park Memorial Institute (RPMI) 1640 media and TrypLETM
Express were purchased from Invitrogen/ GIBCO (U.S.). HypoxyprobeTM-1 Plus Kit was
purchased from hypoxyprobe, Inc (U.S). Flow Cytometry Staining Buffer and Foxp3
permeabilization Buffer were purchased from eBioscience (U.S.). The peptides were synthesized
on a Liberty microwave peptide synthesizer from CEM (U.S.). Nuclear magnetic resonance
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spectra were recorded on Varian (U.S.) 500MHz INOVA spectrometer. 1H NMR chemical shifts
are expressed as δ values (parts per million) and peaks are described as s for singlet and d for
doublet. 13C NMR chemical shifts are expressed as δ values using acetone as an internal
reference. HPLC/MS analyses were performed on a Waters (U.S.) e2695 system equipped with a
Waters 2489 absorption detector and a Waters Qtof Micro electrospray ionization mass
spectrometer. Evaluation and purification of radiolabeled conjugates was performed on a
Waters 1515 binary pump equipped with a Waters 2489 absorption detector and a Bioscan (U.S.)
Flow Count radiometric detector system. A Phenomenex (U.S.) Jupiter 10µ Proteo 250 × 10 mm
semiprep column was used for the purification of bulk amounts of peptides. For the purification
of conjugates, natIn-conjugates, and

111

In-radioconjugates a Phenomenex Jupiter 10µ Proteo

250 × 4.60 mm analytical column was employed. Solid phase extraction was performed using
Empore (U.S.) C18 10 mm high performance extraction disks. The separation of macromolecules
and small molecules was performed using Amicon Ultra (Ireland) Ultracel-10K centrifugal filters
in protein association analysis. Gamma decay detection of

111

In and 125I for the in vitro binding,

receptor saturation, efflux studies and protein binding fractionation studies was accomplished
using a LTI (U.S.) Multi-Wiper nuclear medicine gamma counter. Flow cytometry studies were
performed on BD FACSAria cell sorter (US).
2.2.2 Synthesis of 2-nitroimidazole Acetic Acid (2-NIAA)
The synthesis of 2-NIAA was carried out as reported in the literature by Gariépy and coworkers [126]. A brief description of the two-step procedure is reported below.
Synthesis of 2-Nitroimidazole Ethyl Acetate (2-NIEA): 2-bromoethyl acetate (1.2 mL, 7.18
mmol) was added to a solution of 2-nitroimidazole (1 g, 8.84 mmol) and potassium carbonate
(2.0 g, 14.5mmol) in dry acetonitrile (15 mL). The mixture was stirred for 24 h at room
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temperature, and the resulting precipitate was filtered and washed with acetone. Evaporation
of the filtrate yielded a yellow oil (1.7 g). The pure product was isolated from the crude oil using
flash chromatography (silica gel) eluted with CH2Cl2/MeOH/NH3 (50:7:1) as yellowish oil: 0.9 g
(52.9% yield); Analyses for 2-nitroimidazole ethyl acetate: 1H NMR (CDCl3): 7.260 (d, J = 3.7 Hz,
1H, H-imidazole ring), 7.089 (d, J = 1.5 Hz, 1H, H-imidazole ring), 5.10 (s,2H, NCH2COO), 4.29 (q,
2H, OCH2CH3), 1.30 (t, 3H,OCH2CH3); δc (CDCl3): 166.0 (C=O), 128.5 (CH-imidazole ring), 126.5
(CH-imidazole ring), 62.6 (NCH2COO),50.9 (OCH2CH3), 14.0 (OCH2CH3).
Preparation of 2-Nitroimidazole Acetic Acid (2-NIAA): The purified oil of 2-NIEA (0.9 g) was
mixed into a solution of NaOH (4 N, 2.5 mL), water (10 mL), and MeOH (10 mL). The resulting
solution was stirred at room temperature until no ester derivative was evident by TLC (30 min),
at which point a cation-exchange resin (H+, Bio-Rad, 4 g), which had been protonated by
washing with H2SO4 (1N; 30 mL; pH 2.5) and drying of the filtrate yielded a yellow paste (1.09 g).
Chromatography of crude product on silica gel [mobile phase, CH2Cl2/CH3CN/HCOOH (30:10:1)]
yielded a white crystalline solid: 0.25 g. Analyses for 2-nitroimidazole acetic acid: 1H NMR 1H
(D2O): δH 7.28 (1H, s, H-imidazole ring), 7.06 (1H, s, H-imidazole ring), 4.93 (2H, s, NCH2COO),
3.80 (1H, broad, COOH); 13C NMR(D2O): 172.20 (C=O), 128.03 (CH-imidazaole ring), 127.27 (CHimidazole ring), 52.10 (NCH2COOH).
X-ray Crystallographic Analysis. With respect to X-ray crystallography studies, single crystals
were obtained by slow evaporation of a methanolic solution of 2-NIAA. Crystal data for 2-NIAA:
C5H5N3O4, MW = 171.12 g/mol, monoclinic, space group P21/n, a = 7.3412(8) Å, b = 8.2046(9) Å,
c = 11.5678(13) Å, α = γ = 90°, β = 103.796(2)°, V = 676.65(13) Å3, Z = 4, Dcalc = 1.639 Mg/m3, µ =
0.147 mm-1, T = 100(2) K, Data was collected on a Bruker SMART 1K CCD, Refinement of data
with I > 2σ(I)(1630 independent reflections, Rint = 0.0217) gave a R1(F) = 0.0349 and a wR2(F2) =
0.0946 for all data with a GOF = 1.055. Crystallographic data for the structural analysis has been
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deposited with the Cambridge Crystallographic Data Center (CCDC 838909). Copies of this
information may be obtained free of charge from the CCDC (www: http://www.ccdc.cam.ac.uk)
or from e-mail jcgarrison@unmc.edu
2.2.3 Solid-Phase Peptide Synthesis (SPPS)
Peptide synthesis was performed using an automated solid-phase peptide synthesizer
employing traditional Fmoc chemistry and using a Rink Amide resin. Briefly, the resin (100 µmol
of the resin substituted peptide anchors) was deprotected using piperidine, resulting in the
formation of a primary amine from which the C-terminus of the growing peptide was anchored.
The Fmoc protected amino acids (300 µmol) with appropriate orthogonal protection were
activated with HBTU and sequentially added to the resin. The resulting peptide was orthogonally
deprotected and cleaved from the resin using a cocktail consisting of triisopropyl silane (0.1 ml),
water (0.1 ml), 3,6-dioxa-1,8-octanedithiol (0.1 ml) trifluoroacetic acid (4.625 ml) and
thioanisole (0.075 ml), respectively. The cleaved peptide was subsequently precipitated and
washed using cold (0 °C) methyl-tert-butyl ether (10 ml×3). The crude conjugate was dried by a
centrivap concentrator and weighed. The purity of the crude 1, 2*, 3* and 4* conjugates ranged
from 58-71 % by RP-HPLC. Isolated yields were 17.5, 11.9, 14.7 and 21.0% for 1, 2*, 3* and 4*,
respectively. ES-MS was used to determine the molecular mass of the prepared peptides. All
conjugates were peak purified to ≥ 95% purity and quantified by RP-HPLC prior to in vitro
investigations.
2.2.4 Coupling of 2-NIAA to Bombesin Conjugates
After purification of the conjugates, the 2-nitroimidazole acetic acid was manually coupled
to Ɛ- amino group of the lysine residue for each peptides 2*, 3* and 4* (15 mg each) using
standard amidation chemistry. Briefly, the 2-NIAA (4.95, 9.40, 14.85 mg respectively) was

48
dissolved in M HBTU/DMF (0.45 M, 171 µL) solution followed by addition of DIEA/NMP solution
(2.0 M, 96 µL). This solution was allowed to stand for 15 minutes before addition of the
conjugate in DMF (200 µL). The reaction mixture was stirred for 3 hours at room temperature
and subsequently evaporated to dryness. The residue was re-dissolved in water : acetonitrile
(8:2), peak purified by RP-HPLC and characterized by mass spectrometry. Isolated conjugation
yields were 34.2, 38.7 and 43.4 % for 2, 3 and 4, respectively.
2.2.5 Labeling with natInCl3
For the convenient characterization of the
nat

In was used to substitute for

111

In-Bombesin conjugates, naturally abundant

111

In in the ES-MS and in vitro binding studies. A sample of

conjugates (0.75 mg) was dissolved in ammonium acetate buffer (0.5 M, 200 μL, pH 5.5) and
mixed with a solution of natInCl3 (1.1 mg, 10 μmol). The solution was heated for 60 min at 90 °C.
After cooling to room temperature,

nat

In-conjugates were then peak purified by RP-HPLC.

Isolated yields were 36.7, 29.6, 33.5 and 41.9 % for
respectively. All

nat

In-1,

nat

In-2,

nat

In-3 and

nat

In-4,

nat

In-conjugates were ≥ 95% purity before mass spectrometric characterization

and in vitro binding studies were performed.
2.2.6 Radiolabeling with 111InCl3
A 250 µg sample of the conjugate was dissolved in ammonium acetate buffer (0.5 M, 250 μL,
pH 5.5).

111

InCl3 (1 mCi ) was added to the vial containing the conjugate, and the solution was

heated for 60 min at 90 °C and allowed to cool to room temperature. The resulting
radioconjugates were peak purified using RP-HPLC (≥95%) and concentrated using C18
extraction disk. Elution of the extraction disk with ethanol/sterile saline solution (6:4, 600 μL)
delivered the radioconjugate in high purity. L-ascorbic acid (~20 mg) was added to all
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radioconjugates to reduce radiolysis. Radiolabeling yields for

111

In-1,

111

In-2,

111

In-3 and

111

In-4

were 32.3, 23.6, 26.9 and 36.1 %, correspondingly.
2.2.7 HPLC Purification and Analysis Methodology
When necessary, bulk sample purification was performed using a semi-preparative Proteo
column with a flow rate of 5.0 mL/min. Sample purification for in vitro studies was performed
on analytical Proteo column with a flow rate 1.5 mL/min. HPLC solvents consisted of H2O
containing 0.1% formic acid (solvent A) and acetonitrile containing 0.1% formic acid (solvent B).
For unlabeled and

111/nat

In-conjugates of 1-3, an initial gradient of 85 % A : 15 % B linearly

decreased to 75 % A : 25 % B over a 15 minute time period. For unlabeled and

111/nat

In-

conjugates of 4, an initial gradient of 80 % A : 20 % B linearly decreased to 70 % A : 30 % B over a
15 minute time period. At the end of the run time for all HPLC experiments, the column was
flushed with the gradient 5 % A : 95 % B and re-equilibrated to the starting gradient.
2.2.8 In Vitro Competitive Cell-Binding Studies
For in vitro binding studies, the inhibitory concentration (IC50) for all conjugates and
conjugates were determined using the PC-3 human prostate cancer cell line.
were used as substitutes for the corresponding

nat

In-

nat

In-conjugates

111

In- radioconjugates. Briefly, the PC-3 cells

(~3X104) were suspended in RPMI 1640 media (pH 7.4, 4.8 mg/mL HEPES, and 2 mg/mL BSA)
and incubated at 4°C for 40 min in the presence of radiolabeled [125I-Tyr4]-Bombesin and various
concentrations of the

nat

In-conjugate. At the end of the incubation period, the cells were

centrifuged, aspirated and washed with media a total of four times. The cell associated activity
was measured using a gamma counter and the IC50 values determined by nonlinear regression
using the one-binding site model of Graphpad PRISM 5 (U.S.).
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2.2.9 Flow Cytometric Analysis of Hypoxic Cell Induction
The PC-3 cells were plated at a concentration of 1×106 cells/ well in 6 well plates, and
incubated overnight in normoxic (95% air, 5% CO2) and hypoxic (94.9% N2, 0.1% O2, 5% CO2)
environments. The cells were washed twice with PBS and incubated with 10 µM pimonidazole in
1 ml fresh medium (control well media did not contain pimonidazole) for 2 hours. Cells were
again washed twice with PBS and detached from the well surface using TrypLE for 15 min at
37°C. As per manufacturer’s protocols, 106 cells were treated with Foxp3 permeabilization
solution at 4°C for 30 minutes, washed with buffer and resuspended. The PC-3 cells were
subsequently incubated with the FITC-labeled Hypoxyprobe-1 monoclonal antibody (mAb1)
(1:100 dilution in 0.5% BSA in PBS) in the dark at room temperature for 30 minutes. The stained
cells were washed once, fixed in paraformaldehyde and subject to flow cytometric analysis. Cells
were analyzed using a FACSAria instrument and FloJo software.
2.2.10 Receptor Saturation Binding Assays
Receptor saturation studies were performed on PC-3 cells under normoxic (95% air, 5% CO2)
and hypoxic (94.9% N2, 0.1% O2, 5% CO2) conditions. PC-3 cells (3×104/well) were incubated
overnight in 24-well plates at 37°C in RPMI 1640 media (pH 7.4, 4.8 mg/mL HEPES, and 2 mg/mL
BSA) in hypoxic conditions. On the day of the experiment, the cells were seeded with fresh
culture medium and incubated for 4 hour under normoxic or hypoxic conditions. Upon
completion of the incubation, PC-3 cells were incubated with (30,000 cpm) [125I-Tyr4]-Bombesin
and a series of [Tyr4]-Bombesin concentrations ranging from 0.469 nM to 120 nM for 1 hour at 4
°C. Non-specific binding was determined using 3 µM of the [Tyr4]-Bombesin in the presence of
the radioligand. At the end of the incubation time cells were aspirated and washed thrice with
cold media and the remaining radioactivity was measured by solubilizing the cells with 10% SDS.
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Non-linear regression analysis was then performed using Graphpad PRISM 5 (U.S.) to determine
the Bmax and Kd values for each experiment.
2.2.11 Efflux Studies
Efflux studies were performed using PC-3 cells under normoxic (95% air, 5% CO2) and
hypoxic (94.9% N2, 0.1% O2, 5% CO2) conditions. PC-3 cells were incubated in six-well plates (0.5
× 106 / well) under hypoxic conditions overnight in RPMI 1640 media (pH 7.4, 4.8 mg/mL HEPES,
and 2 mg/mL BSA). On the day of the experiment, the medium was removed, and the cells were
washed with cold medium and incubated for 4 hour under normoxic and hypoxic condition. Cells
were incubated for an additional 2 hour at 37°C in the presence of 100,000 cpm of each

111

In-

radioconjugate. Upon completion of the incubation at timepoints 0, 30, 60, 90 and 120 min, cells
were washed thrice with media to discard the unbound peptide. Surface bound radioactivity
was removed by washing the cells twice with an acid wash (50 mM glycine-HCl/0.1 M NaCl
buffer, pH 2.8). The cells were then lysed at 37°C using a 10 % aqueous SDS solution. The
radioactivity of the effluxed, surface bound and internalized fractions for each radioconjugate
was determined using a gamma counter. Statistical analyses were performed by two-way
analysis of variance (ANOVA) using Graphpad PRISM 5 (U.S.).
2.2.12 Cellular Protein Analysis
For the cellular fractionation studies, the procedure for the preparation of normoxic and
hypoxic PC-3 was carried out as outlined in the efflux studies above. On the day of the
experiment, the medium was removed, and the cells were washed with warm medium and
incubated for 4 hours under normoxic and hypoxic conditions. PC-3 cells were incubated for an
additional 2 hours at 37°C in the presence of 30,000 cpm of each

111

In-radioconjugate. At the

end of this time, the cells were washed thrice with warm medium to remove the unbound,
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extracellular radioconjugates and allowed to incubate for an additional hour at 37°C.
Subsequently, PC-3 cells were washed thrice with PBS and lysed using 1ml of M-PER at 37°C. The
cellular debris was centrifuged down and the supernatant was then transferred to an Amicon
Ultracel 10k filter device with an extra PBS (1ml). The samples were centrifuged at 4000×g for 10
minutes and washed with PBS (1ml×2) per wash. The radioactivity associated with the molecular
weight fractions was determined using a gamma counter.
2.3 RESULTS
2.3.1 Synthesis of 2-nitroimidazole Acetic Acid (2-NIAA)
In order to couple the 2-nitroimidazole to the BB2r-targeted peptide conjugates, the acetic
acid derivative was synthesized as outlined in literature procedures.[126] Initially, the 2nitroimidazole ethyl acetate was synthesized by formation of the potassium 2-nitroimidazole
salt and subsequent reaction with 2-bromoethyl acetate. Conversion of the 2-nitroimidazole
ethyl acetate to the acetic acid derivative was achieved using a cation exchange column pretreated with dilute H2SO4 prior to elution. The chemical constitution of 2-NIAA was confirmed by
NMR and single crystal x-ray crystallography. All 1H and 13C NMR data agreed with literature
values. The molecular structure of 2-NIAA is depicted in Figure 2.2.
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Figure 2.2 An ORTEP representation of the 2-aitroimidazole acetic acid
An ORTEP representation of the 2-NIAA with thermal ellipsoids drawn at 50% probability.
Selected bond lengths (Å) and angles (deg): O(1)-N(3) = 1.2223 (15), O(2)-N(3) = 1.2309 (14),
N(3)-C(1) = 1.4387 (17), N(1)-C(1) = 1.3572 (16), N(2)-C(1) = 1.3161 (16), C(2)-C(3) = 1.372 (2),
O(3)-C(5)= 1.2012 (16), O(4)-C(5) = 1.3206 (16), C(4)-C(5)= 1.5144 (17), O(1)-N(3)-O(2) = 125.13
(12), O(1)-N(3)-C(1) = 117.15 (11), O(2)-N(3)-C(1) = 117.71 (11), O(3)-C(5)-O(4) = 126.24 (12),
O(3)-C(5)-C(4)=124.77 (12), O(4)-C(5)-C(4)=108.98(11).
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2.3.2 Conjugate Synthesis and Radiolabeling
The conjugates were synthesized using standard solid-phase peptide synthesis. Specifically,
four radioconjugates were synthesized using the DOTA-X-BBN(7-14)NH2 paradigm (Figure 2.1).
The conjugates were purified by RP-HPLC and isolated with yields of 17.5, 11.9, 14.7 and 21.0 %
for conjugates 1, 2*, 3* and 4*, correspondingly. RP-HPLC retention times and mass
spectrometric identification of the conjugates are listed in Table 2.1. Subsequently, 2-NIAA was
coupled to the Ɛ-amino group of lysine residue(s) of the conjugates using HBTU, DIEA and NMP
in DMF. Analysis by RP-HPLC revealed that the coupling reactions were completed within 3
hours. The products obtained were consequently purified by RP-HPLC and characterized by ESMS (Table 2.1). The yields of conjugates 2, 3 and 4 were 34.2, 38.7 and 43.3 %, respectively.
Labeling and purification of the conjugates with natIn and 111In were carried out under nearly
identical conditions. In brief, 111/natInCl3 was incubated with the desired conjugate in ammonium
acetate buffer (0.1M, pH 5.5) at 90°C for 1 hour. Radiolabeling yields for
and

111

111

In-1,

111

In-2,

In-4 were 32.3, 23.6, 26.9 and 36.1 %, correspondingly. Purification of the

111

In-3

111/nat

In-

conjugates was accomplished by RP-HPLC. Concentration of RP-HPLC eluent was achieved by
solid phase extraction on C18 column with typically ≥ 90% recovery. Prior to in vitro analysis,
111

In-1-4 were found to have 99.0, 99.3, 97.7 and 95.3% radiochemical purity, correspondingly,

as determined by RP-HPLC. Retention times and mass spectrometric characterization of the
nat

In-conjugates are given in Table 2.1.
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Molecular
Formula
1467.7

MS
Calculated

1553.4

1468

MS
a
Observed

6.5

11.1

14.99

RP-HPLC
b
Retention Time

-

-

-

10.2 ± 3.5

IC50 /nM

Table 2.1 Mass spectrometric and RP-HPLC characterization of conjugates

C67H106N18O17S
1553.8

1639. 5

9

10.8 ± 2.8

C75H112N23O21SIn

C67H103N18O17SIn

C92H136N32O28S

C83H124N28O25S

2058.9

1819.7

1580.5

2170

1945.9

2283.2

2058.6

1819.5

1580.2

2170.4

1946.1

15.04

14.19

12.67

15.94

14.76

14.01

342 ± 99.0

93.0 ± 37.3

5.70 ± 1.31

23.5 ± 15.9

1110 ± 205.0

48.5 ± 27.1

c

C70H112N20O18S

1639.8

1711.3

12.05

Analog

C73H118N22O19S

1710.9

1707.1

1

DOTA [(D)K - (D)K -G] –BBN(7-14)
NH2
C77H127N23O19S

1706.8

DOTA-8 AOC–BBN(7-14) NH2
DOTA [(D)K - 5- AVA] –BBN(7-14)
NH2

3*
DOTA [(D)K - (D)K - (D)K ] –BBN(714) NH2
C75H115N23O21S

2*

4*
DOTA [(D)K (2-NIAA)- 5- AVA] –
BBN(7-14) NH2
DOTA [(D)K (2-NIAA)- (D)K (2-NIAA)G] –BBN(7-14) NH2
DOTA [(D)K (2-NIAA)- (D)K (2-NIAA)(D)K (2-NIAA) ] –BBN(7-14) NH2
In-DOTA-8 AOC–BBN(7-14) NH2

C83H121N28O25SIn

2283.1

In. b RP-HPLC methods described in Materials and Methods

C92H133N32O28SIn
nat

2
3
4
In-1
In-2
In-3
In-4

In-DOTA [(D)K (2-NIAA)- 5- AVA] –
BBN(7-14) NH2
In-DOTA [(D)K (2-NIAA)- (D)K (2NIAA)-G] –BBN(7-14) NH2
In-DOTA [(D)K (2-NIAA)- (D)K (2NIAA)- (D)K (2-NIAA) -G] –BBN(7-14)
NH2

a
For convenient mass spectra analysis 111In was replaced by
section. c Values represent mean ± SEM. (n=6)
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2.3.3 In Vitro Competitive Cell-Binding Studies
The BB2r binding affinity of the unlabeled and

nat

In Bombesin conjugates were assessed by

competitive binding assays performed at 4°C using the BB2r-positive human prostate cancer PC3 cell line. All conjugates and

nat

In-conjugates were able to displace [125I-Tyr4]-Bombesin from

BB2r binding sites on the PC-3 cell membranes in a dose-dependent manner. For

nat

In-labeled

conjugates, conjugates 1 and 2 demonstrated the highest affinity binding (5.70 ± 1.31, 23.5 ±
15.9 nM) to the BB2r. Conjugates 3 and 4 exhibited substantially poorer binding affinity, relative
to 1 and 2, with affinities of 93.0 ± 37.3 nM and 342 ± 99 nM, correspondingly. Some differences
in binding affinity were observed between unlabeled and

nat

In-labeled conjugates, but analysis

of the data revealed no overall trend.
2.3.4 Hypoxia Staining and Fluorescence Analysis
Before beginning hypoxia experiments, the conditions used for the generation of hypoxic
cells were validated by hypoxia staining. PC-3 cells were placed under hypoxic or normoxic
conditions overnight and were subsequently exposed to pimonidazole for 2 hours.
Pimonidazole, a 2-nitroimidazole based agent, has been widely used for the detection and
quantification of hypoxia.[127-129] After exposure to pimonidazole, the cells were
permeabilized and incubated with a FITC-conjugated primary antibody against pimonidazole
adducts. The fluorescence analysis of the stained PC-3 cells by flow cytometry is depicted in
Figure 2.3. Mean fluorescence of the normoxic PC-3 cells treated with pimonidazole was 56.8.
Treatment of hypoxic PC-3 with the hypoxia staining agent yielded a significant increase in
antibody binding with a mean fluorescence of 286. The increase in antibody binding for the
hypoxic cells corresponds, as expected, with an increase in hypoxia staining due to a drop in the
O2 concentration. Based on previous literature reports, the values from this study are consistent
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with hypoxia being generated in the PC-3 cells and therefore subsequent in vitro studies were
carried out employing the hypoxia generating conditions of this experiment.[127]
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Control
Normoxic
Hypoxic

Figure 2.3 Flow cytometric analysis of pimonidazole binding
Flow cytometric analysis of pimonidazole binding under control (no pimonidazole), normoxic
(95% air, 5% CO2) and hypoxic (94.9% N2, 0.1% O2, 5% CO2) conditions in PC-3 cells.
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2.3.5 Receptor Saturation Binding Assays
In order to determine if and to what extent the receptor expression changes under hypoxic
conditions, receptor saturation studies were performed to quantify the receptor expression in
PC-3 cells under normoxic and hypoxic conditions. The receptor saturation assays revealed that
under normoxic and hypoxic conditions there were 0.35 ± 0.08 million and 0.30 ± 0.06 million
binding sites, respectively, per PC-3 cell. The dissociation constant (Kd) values were found to be
1.0 ± 0.05 nM and 0.9± 0.08 nM, correspondingly, for normoxic and hypoxic PC-3 cells. Under
the conditions of our experiments, these receptor saturation studies indicate that the BB2r
expression at the cell surface does not significantly change with oxygen levels.
2.3.6 Efflux Studies
To evaluate the ability of the 2-nitroimidazole hypoxia trapping moieties to enhance the
retention of the BB2r-targeted drugs, efflux studies were performed under normoxic and
hypoxic environments to determine the rate at which the
were effluxed from the PC-3 cells. In these studies,

111

In-labeled radioconjugates 1 - 4

111

In-1, which does not have a 2-

nitroimidazole incorporated into the structure of the radioconjugate, is the control and will be
used to compare the relative effectiveness of the hypoxia trapping conjugates (111In-2-4) in both
hypoxic and normoxic conditions.
The radioconjugates were incubated in the presence of the PC-3 cells for 2 hours prior to the
start of the efflux studies. During this incubation time period,

111

In-1 and

111

In-2 demonstrated

significant accumulation of the radioactivity with 22.6 and 20.5 %, respectively, of the added
radioconjugates

internalized

under

normoxic

conditions. The

same radioconjugates

demonstrated a marked decline in overall uptake under hypoxic conditions with 17.8 and 15.0 %
internalized, respectively, in the same time span. In comparison,

111

In-3 and

111

In-4
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demonstrated internalization of only 1.4 and 0.8 %, correspondingly, of the added radioactivity
under normoxic conditions. Under hypoxic conditions, the

111

In-3 and

111

In-4 radioconjugates

exhibited uptakes of 1.3 and 1.2 %, respectively, during the incubation period. Comparison of
the internalization of the radioconjugates revealed that internalization corresponded well with
the binding affinities observed in the competitive binding assays. Also, internalization under
hypoxic conditions yielded significantly lower uptake for 111In-1 and 111In-2 relative to 111In-3 and
111

In-4.
The efflux of the radioconjugates over time viewed as a percentage of the initial internalized

activity is depicted in Figure 2.4. At all timepoints investigated, the radioconjugates
demonstrated significantly higher retention of the radioconjugates under hypoxic conditions
relative to normoxic. In the normoxic studies, the

111

In radioconjugates 1-4 demonstrated

substantial efflux with 32, 55, 31 and 29 %, respectively, of the radioactivity material being
externalized within the first 30 minutes of the experiment. Under hypoxic conditions
radioconjugates 1-4 exhibited significantly lower clearance of the radioactivity with 5, 14, 11 and
13 % of the intracellular radioactivity being externalized from the cell. After the initial 30 minute
timepoint, the rate of clearance of the radioactivity substantially declined under both normoxic
and hypoxic conditions. With the exception of

111

In-2, the radioconjugates demonstrated an

increased retention of 20-30 % of the initial internalized activity under hypoxic relative to
normoxic conditions. Interestingly,

111

In-2 exhibited a 50% increase in retention under hypoxic

conditions which is significantly higher than the other radioconjugates.
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Figure 2.4 Efflux assays for the 111In-radioconjugates in PC-3 cells
Efflux assays depicted as percentage of initial internalized activity for the 111In-radioconjugates
in PC-3 cells. Values are mean ± SEM (n=3).
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An alternative way to view the effect hypoxia has upon the clearance of the radioconjugates
is by directly comparing the internalized activity of the radioconjugate for each timepoint under
normoxic and hypoxic conditions. The hypoxia enhancement factor (HEF) is the ratio of the
internalized activity of the radioconjugate under hypoxic conditions over the internalized
activity observed under a normoxic environment. The HEF ratios for each radioconjugate at each
timepoint are depicted in Figure 2.5. With the exception of 111In-4, all of the radioconjugates at
the initial timepoint demonstrated favored retention of the radioconjugates in normoxic
conditions. Although, by the 30 minute timepoint, all of the radioconjugates displayed
significantly higher retention in hypoxic relative to normoxic cells (i.e. HEF > 1). This observation
corresponds with the substantially higher clearance of the radioconjugates under normoxic
relative to hypoxic conditions noted during the first 30 minutes of the efflux experiment. From
30 to 120 minutes, the 111In-labeled radioconjugates 1–4 demonstrated an average HEF ratio of
1.08 ± 0.03, 1.58 ± 0.15, 1.27 ± 0.12 and 1.83 ± 0.17, respectively. The radioconjugates 111In-2-4
exhibited significantly (p < 0. 001 – 0.05) higher average HEF ratios compared to control (i.e.
111

In-1). However, the HEF ratios of 111In-3 were substantially lower than that of either 111In-2 or

111

In-4. For 111In-1, the control for this experiment, the radioconjugate exhibited no higher than

a 10% increase in retention under hypoxic conditions from time points 30 to 120 minutes.

HEF: Hypoxic/Normoxic
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Figure 2.5 HEF ratios for the efflux studies of 111In-BB2r-targeted radioconjugates
HEF ratios for the efflux studies of

111

In-BB2r-targeted radioconjugates under normoxic (95%

air, 5% CO2) and hypoxic conditions (94.9% N2, 0.1% O2, 5% CO2). Values are mean ± SEM
(n=3).
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2.3.7 Cellular Protein Analysis
In a hypoxic environment, 2-nitroimdazoles undergo reduction and eventual irreversible
conjugation with intracellular nucleophiles. It has been estimated that approximately 20% of
such adduct formations are with nucleophilic groups (e.g. thiols) on proteins.[130, 131] In order
to better evaluate the protein binding capabilities of the 2-nitroimidazole containing BB2rtargeted agents, the protein association properties of 111In-2 was evaluated against the controls,
111

In-1 and [125I-Tyr4]BBN, under hypoxic and normoxic environments. The radioconjugates 111In111

3 and

In-4 were not evaluated because of the poor internalization of these analogs. After 2

hours of incubation with the radioconjugates under hypoxic or normoxic conditions, the PC-3
cells were lysed using a protein extraction reagent, centrifuged and the supernatant filtered
using a 10 kDa centrifugal filter. Analysis of the protein associated radioactivity as a percentage
of total intracellular activity is depicted in Figure 2.6. The radioconjugates

111

In-1 and [125I-

Tyr4]BBN both demonstrated similar levels, approximately 3.15 to 5.60 %, of protein association
during the timespan of the experiment. Statistical analysis of the 111In-1 and [125I-Tyr4]BBN data
revealed no significant impact on protein association under hypoxic or normoxic conditions. For
the

111

In-2 radioconjugate, the protein association under normoxic conditions was statistically

the same as those found in controls. However, 111In-2 demonstrated a protein association under
hypoxic conditions of approximately 13 % which was three fold higher than that observed under
a normoxic environment. These findings strongly imply that the mechanism of protein retention
of 111In-2 is associated with the 2-nitroimidazole moiety and is oxygen dependent.
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Figure 2.6 Protein association studies for 111In-1, 111In-2 and [125I-Tyr4]-BBN
Protein association studies for 111In-1, 111In-2 and [125I-Tyr4]-BBN under normoxic (95% air, 5%
CO2) and hypoxic (94.9% N2, 0.1% O2, 5% CO2) conditions in PC-3 cells. Values are mean ± SEM
(n=3).
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2.4 DISSCUSSION
In the area of cancer diagnostics and therapeutics, targeted, low molecular weight agents,
such as those based on small peptides, sugars and steroids, generally offer the advantage of
rapid tumor targeting and swift clearance from non-target tissues relative to the analogous large
molecular weight counterparts (e.g. antibodies, nanoparticles, etc.).[132-135] However, one
significant challenge with low molecular weight, targeted agents has been obtaining optimal
retention in the target tissue due to significant clearance of the radiotracer from the tumor.
Since most of the targeted agents develop maximal accumulation in the target site within a
short time (i.e. 15 min to 1 hour) after administration, it would be advantageous to develop
techniques to selectively increase retention in the tumor thereby increasing the diagnostic and
therapeutic efficacy of the agents.
Tumor hypoxia is the result of the inefficiency of the vascular architecture to adequately
deliver nutrients, such as oxygen, to areas within the tumor. Since it has been demonstrated
that human cancers, including prostate cancer, have significant levels of hypoxia, the
development of hypoxia targeted drugs for both diagnostic and therapeutic applications in
cancer has been an active area of research.[104, 115, 136-140] In particular, 2-nitroimidazole
derivatives, which selectively reduce and become trapped within hypoxic cells, have been
among the most thoroughly investigated class of hypoxia selective agents. This study seeks to
design BB2r-targeted agents that incorporate the hypoxia selective trapping agent 2nitroimidazole into the linking group of the radioconjugate. It is estimated that upon reduction
and activation of the 2-nitroimidazole approximately 20% of the hypoxia selective agent become
irreversibly conjugated to proteins within the cell.[131] In order to determine if one or more 2nitroimidazoles would increase the retention of the radioconjugate in hypoxic cells,

111

In-2-4,

were synthesized with one, two or three 2-nitroimidazoles, respectively, incorporated into the
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linking group of the radioconjugate. Radioconjugate

111

In-1 is a thoroughly investigated BB2r-

targeted peptide that does not contain 2-nitroimidazole moieties and thus was used as the
control in our experiments.[124]
Synthesis of the

111

In-labeled radioconjugates 1-4 began with the synthesis of the 2-NIAA

according to literature procedures.[126] The 2-NIAA was thoroughly characterized by NMR and
the structural constitution of the moiety confirmed by x-ray crystallography. Conjugates 1 and 24* were synthesized and purified by RP-HPLC in fairly low yields (12-22 %). Coupling of the 2NIAA to the conjugates 2*-4* was accomplished using standard amidation chemistry. Further
purification of 2-4 by RP-HPLC provided the conjugates in modest yields (34 - 44 %).
Radiolabeling of conjugates 1-4 proceeded easily and with high purity (≥ 95%) using standard
radiolabeling conditions.[124]
In vitro competitive BB2r binding assays of

111

In-1-4 were performed using PC-3 cells with

[125I-Tyr4]-Bombesin as the competitive radioligand. For the natural indium labeled conjugates,
these studies demonstrated the following trend: 111In-2 > 111In-1 > 111In-3 > 111In-4. Analyzing the
structure-activity relationship with respect to binding affinity, it was determined that inclusion
of more than one 2-nitroimidazole in the linking group had an unfavorable effect on the binding
affinity of the radioconjugate. This strongly indicates that the 2-nitroimidazoles are interfering,
through charge or sterics, with the ability of the pharmacophore (i.e. BBN(7-14)NH2) to bind
strongly to the BB2r. Since the pKa of 1-substituted-2-nitroimidazoles, such as misonidazole, are
generally significantly below physiological pH, the 2-nitroimidazoles are likely not charged.[141,
142] Given this, it is probable that the loss in binding affinity in 111In-3 and 111In-4 are primarily a
result of steric interference of the 2-nitroimidazole trapping moieties with the BB2r-targeting
vector. Based on the

111

In-2 radioconjugate, the inclusion of a linker between the 2-

nitroimidazole-amino acid residue and the pharmacophore of at least five carbon lengths is
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needed to achieve more optimal binding. This need for adequate spacers will be considered
when designing future 2-nitroimidazole containing radioconjugates.
In order to examine the effect hypoxia has on the uptake and retention of the designed 111In
labeled radioconjugates, the conditions for the generation of hypoxic PC-3 cells was first
validated. For this purpose pimonidazole, a well-known and commonly used agent for the
assessment of cellular hypoxia, was used for the confirmation of hypoxia generation in PC-3
cells.[127-129] The targeting mechanism of the pimonidazole utilizes the same 2-nitroimidazole
moiety employed in the design of the 111In-2-4 radioconjugates. Exposure of PC-3 cells incubated
under the hypoxic conditions of our studies revealed a fivefold increase in pimonidazole binding
compared to PC-3 cells incubated under normoxic conditions as determined by flow cytometry.
These results are consistent with similar hypoxia analysis utilizing pimonidazole.[127] Since
pimonidazole utilizes the same 2-nitroimidazole moiety for hypoxia targeting as the 111In labeled
radioconjugates in our study, the cellular hypoxia generated utilizing our conditions were
determined to be sufficient for the evaluation of the BB2r expression and the efficacy of the
radioconjugates in PC-3 cells.
The design of targeted agents that are selectively enhanced toward hypoxic cells requires an
understanding of the expression of the target under normoxic as well as hypoxic conditions.
Since these agents gain entry into the cell through receptor-mediated endocytosis, if expression
of the receptor target is significantly down-regulated under hypoxic conditions, any
enhancement in hypoxic retention is likely to be substantially inhibited. Conversely, if under
hypoxic conditions the target increases in expression; both the targeting and hypoxia
enhancement of the drug would be expected to be improved. With this in mind, receptor
saturation studies were undertaken to evaluate the expression of the BB2r on the surface of the
PC-3 cells under hypoxic and normoxic conditions. From these studies, it was determined that

69
the BB2r expression was 0.35 ± 0.08 and 0.30 ± 0.06 million receptors per PC-3 cell under
normoxic and hypoxic conditions, correspondingly. During this study, oxygen levels, at least
throughout the course of our investigation, did not play a significant role in the surface receptor
expression of the BB2r. These findings are in accordance with a report from Martínez and
colleagues of the BB2r expression in the H209 human lung cancer cell line under normoxic and
hypoxic conditions.[143] With respect to overall BB2r expression of the PC-3 cells, the values
obtained agree well with other reports.[144]
Efflux studies were performed under normoxic and hypoxic conditions to evaluate the
efficacy of the hypoxia trapping moieties to enhance retention in hypoxic cells. The initial 2 hour
incubation of the radioconjugates with the PC-3 cells yielded a bimodal uptake pattern. 111In-1,
the control for our experiment, and
dose, respectively) uptake, while

111

In-2 demonstrate significant (22.6 % and 20.5 % of the

111

In-3 and

111

In-4 exhibited significantly lower internalization

(1.4 % and 0.8 %, respectively). Based on the in vitro binding data, the significant decline in
internalization with respect to

111

In-3 and

these radioconjugates relative to

111

In-4 is likely due to the poor receptor affinity of

111

In-1 and

111

In-2. Interestingly, for some of the

radioconjugates, oxygen levels seemed to have a significant effect on the initial uptake values of
the radioconjugates. This is particularly true for

111

In-1 and

111

In-2 in which a significant

reduction of 25 % was observed under hypoxic conditions for both radioconjugates. The cause
for this decline is unknown; however, it was interesting to note that within the first 30 minutes
of the efflux study at normoxia, all radioconjugates undergo substantial decline (29 – 55 %) to
levels that are significantly below that of the hypoxic levels. Contrarily, for the hypoxic studies,
the amount of internalized activity declined relatively little (5 - 15 %) during the same time
period. Further investigations are needed to elucidate the exact cause for these contrasting
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observations. After the initial 30 minute timepoint, there was relatively little decline in
internalized activity among the radioconjugates.
As stated earlier, normoxic levels of internalized activity initially were greater, excepting
111

In-4, in normoxic rather than the hypoxic studies. Although by 30 minutes, the situation had

reversed itself with all radioconjugates demonstrating hypoxic/normoxic ratios greater than
one. The radioconjugate 111In-4 demonstrated the highest average hypoxia enhancement (1.83 ±
0.17) followed closely by

111

In-2 (1.58 ± 0.15). Interestingly,

enhancement of 1.27 ± 0.12 compared to

111

In-2. Given that

moieties in comparison to one incorporated into

111

In-3 has a fairly low average

111

In-3 has two 2-nitroimidazole

111

In-2, the lower hypoxia enhancement is

unexpected. The reason for this circumstance is not clear. Remarkably, even the control in our
experiment,

111

In-1, demonstrated a small (≤ 10 %) increase in retention under hypoxic

conditions. Speculatively, the retention in the control under hypoxic conditions may be
attributed to slower metabolism kinetics or other hypoxia-impaired cellular functions needed to
efflux the radioconjugates. Ultimately, more studies, which are in progress, are needed to
obtain a clearer understanding of this process. Nevertheless, all of the experimental
radioconjugates (i.e.

111

In-2-4) demonstrated significantly higher hypoxia enhancement than

observed in the control, strongly suggesting that 2-nitroimidazoles are at least partially
responsible for this enhancement.
It is well known that 2-nitroimidazole derivatives based on small molecules bind irreversibly
to proteins under hypoxic conditions.[127, 128, 131] In order to elucidate whether or not BB2rtargeted agents employing 2-ntiroimidazoles can conjugate to proteins, the cellular protein of
the PC-3 cells were isolated after incubation with 111In-1, 111In-2 and [125I-Tyr4]BBN under hypoxic
and normoxic conditions. The controls,

111

In-1 and [125I-Tyr4]BBN, demonstrated 3.15 to 5.60 %

association with the proteins under both normoxic and hypoxic conditions. Statistical analysis of
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the difference between the hypoxic and normoxic protein association for the controls revealed
no statistically significant difference (p > 0.05). Since the controls do not contain reactive
moieties that would be expected to irreversibly bind to macromolecules, the protein association
for the controls are most likely due to reversible, non-specific binding. Under normoxic
conditions the

111

In-2 radioconjugate demonstrated similar protein association as controls.

However, under hypoxic conditions the

111

In-2 radioconjugate demonstrated a threefold

increase in protein association (p < 0.001). These results indicate that the increase in protein
association of 111In-2 is oxygen dependent and is consistent with the trapping mechanism of the
2-nitroimidazole. While the exact binding mode of the 111In-2 with proteins is not known beyond
doubt, the findings from a superfluity of 2-nitroimidazole literature and the results of this study
lead us to the conclusion that the increased protein association of the
likely irreversibly bound to the proteins. Assuming the

111

In-2 radioconjugate is

111

In-2 protein association under

normoxic conditions is reversible, non-specific binding, the increased protein association of the
radioconjugate under hypoxic conditions signifies that ~ 10 % of the internalized cellular activity
is likely irreversibly bound to cellular proteins.
2.5 CONCLUSION
In conclusion, we have synthesized and evaluated three BB2r-targeted radioconjugates that
have 2-nitroimidazole hypoxia trapping moieties conjugated to the linking group of the peptide
for the purpose of enhancing retention in hypoxic cancers. Our studies indicate that placement
of the 2-nitroimidazole moieties close to the pharmacophore has a detrimental effect on the
ability of the radioconjugate to adequately bind to the BB2r. The BB2r-targeted agents that
include 2-nitroimidazole moieties demonstrated improved longitudinal retention in hypoxic
relative to normoxic PC-3 cells. Additionally, we found that the inclusion of 2-nitroimidazole
moieties in the BB2r-targeted agent design significantly increases protein association, by a likely
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irreversible conjugation reaction, under hypoxic conditions. Also, evaluation of the PC-3 human
prostate cancer cell line reveals that the BB2r expression is not dependent on oxygen levels and
suggests that the BB2r would therefore still be a valid target on the hypoxic fraction of BB2rpostive prostate cancer cells. While further work is still needed, this work suggests a potential
new avenue to significantly increase the cellular retention of many targeted agents in hypoxic
cancers. Our future work will focus on elucidating the mechanisms of retention of the hypoxia
enhanced BB2r-targeted agents and evaluating the efficacy of these agents in in vivo cancer
models.
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Chapter 3 Synthesis and In Vitro/In Vivo Evaluation of Hypoxia-Enhanced 111In-Bombesin
Conjugates for Prostate Cancer Imaging2
3.1 INTRODUCTION
As mentioned in Chapter 2, the disadvantage of many small molecules based, peptidetargeted radiotracer is low retention at the tumor site due to intrinsically high diffusion and
efflux rates. This can substantially reduce the diagnostic and therapeutic efficacy of the agent as
well as its potential for clinical translation.
We have previously demonstrated that these hypoxia-enhanced BB2r-targeted peptides
significantly increase retention in hypoxic PC-3 human prostate cancer cells [145]. From these
studies, it was determined that the proximity of the 2-nitroimidazole relative to the
pharmacophore had a substantial impact on BB2r binding affinity. Herein, we present the
synthesis and in vitro properties of hypoxia-enhanced BB2r-targeted radioconjugates with
extended linking groups to improve BB2r binding affinity. Additionally, utilizing biodistribution
and microSPECT/CT imaging studies, we report the first in vivo investigation of these agents in a
PC-3 xenograft mouse model.
3.2 MATERIALS AND METHODS
3.2.1 Chemical and Supplies
Unless otherwise noted all solvents were used without further purification. Deionized water
was purified by a Millipore (U.S.) Mili-Q-Biocel. Acetonitrile, formic acid, N, Ndiisopropylethylamine (DIEA), N,N-dimethylformamide (DMF), dichloromethane (DCM), N,N'dicyclohexylcarbodiimide (DCC) , N-methylpyrrolidone (NMP), thioanisol, sodium hydroxide, L2

The material presented in this Chapter was previously published: Zhou Z, Wagh NK, Ogbomo SM, Shi W,
Jia Y, Brusnahan SK, Garrison JC. Synthesis and in vitro and in vivo evaluation of hypoxia-enhanced 111Inbombesin conjugates for prostate cancer imaging. J Nucl Med, 2013. 54(9): p. 1605-12.
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ascorbic acid, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), bovine serum
albumin (BSA) and sodium dodecyl sulfate (SDS) were purchased from Fisher Scientific (U.S.). 2nitroimidazole was purchased from Amfinecom (U.S.). O-Benzotriazole-N,N,N’,N’-tetramethyluronium-hexafluoro-phosphate (HBTU), Fmoc-protected natural amino acids and the
appropriate Rink Amide resins were purchased from Nova Biochem (U.S.). Fmoc-8-AOC was
purchased from CreoSalus (U.S). Roswell Park Memorial Institute (RPMI) 1640 media, phosphate
buffered saline (PBS), and mammalian protein extraction reagent (M-PER) were purchased from
Thermo Scientific (U.S.). Indium-111 chloride (111InCl3) was purchased from MDS Nordon
(Canada). Naturally abundant indium chloride (natInCl3), triisopropyl silane and 3, 6-dioxa-1, 8octanedithiol were purchased from Sigma-Aldrich (U.S.). The [125I-Tyr4]-Bombesin was purchased
from Perkin Elmer (U.S.). Prostate cancer (PC-3) cell lines were obtained from American Type
Culture Collection (U.S.) and cultured under vendor recommended conditions. TrypLETM Express
was purchased from Invitrogen (U.S.). The separation of macromolecules and small molecules
was performed using Amicon Ultra (Ireland) Ultracel-30K centrifugal filters in protein association
analysis. Four week-old Institute of Cancer Research severely combined immunodeficient (ICR
SCID) mice were obtained from Charles River Laboratories (Wilmington, MA). Food and water
were given ad libitum. Each animal was kept in individual cage with an air filter cover under
light- (12 h light/dark cycle) and temperature-controlled (22±1°C) environment. The animals
were treated in accordance to the Principles of Animal Care outlined by National Institutes of
Health and approved by the Institutional Animal Care and Use Committee of the University of
Nebraska Medical Center.
3.2.2 Equipment
The peptides were synthesized on a Liberty microwave peptide synthesizer from CEM (U.S.).
HPLC/MS analyses were performed on a Waters (U.S.) e2695 system equipped with a Waters
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2489 absorption detector and a Waters Qtof Micro electrospray ionization mass spectrometer.
Evaluation and purification of radiolabeled conjugates was performed on a Waters 1515 binary
pump equipped with a Waters 2489 absorption detector and a Bioscan (U.S.) Flow Count
radiometric detector system. A Phenomenex (U.S.) Jupiter 10µ Proteo 250 × 10 mm semiprep
column was used for the purification of bulk amounts of peptides. The peptides were
concentrated on a Centrivap (U.S.) Centrifugal Concentrator. For the purification of conjugates,
nat

In-conjugates, and

111

In-radioconjugates a Phenomenex Jupiter 10µ Proteo 250 × 4.60 mm

analytical column was employed. Solid phase extraction was performed using Empore (U.S.) C18
10 mm high performance extraction disks. Hypoxic PC-3 cells were incubated in hypoxic glove
box with temperature, CO2 and humidity controller (Coy Laboratory Products INC, Grass Lake,
MI). Gamma decay detection of 111In and 125I for the in vitro binding, receptor saturation, efflux
studies and protein binding fractionation studies was accomplished using a LTI (U.S.) MultiWiper nuclear medicine gamma counter. Gas anesthesia was administered at a vaporizer setting
of 5% isoflurane (Halocarbon Corp, River Edge, NJ) with 0.5 L/min oxygen using an E-ZAnesthesia
apparatus (EUTHANEX Corp, Palmer, PA). Biodistribution radiation measurements were made
with a NaI (Tl) well detector constructed by AlphaSpectra, Inc. (U.S.). Small animal SPECT/CT
data acquisition is achieved with the dual Flex Triumph CT/SPECT instrument (GE Healthcare,
Gamma-Medica Ideas, Northridge, CA).
3.2.3 Cell Lines and Xenograft Models
Prostate cancer (PC-3) cell lines were obtained from American Type Culture Collection (U.S.)
and cultured under vendor recommended conditions. All animal experiments were conducted in
accordance to the Principles of Animal Care outlined by National Institutes of Health and
approved by the Institutional Animal Care and Use Committee of the University of Nebraska
Medical Center. Four week-old Institute of Cancer Research severely combined immunodeficient
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(ICR SCID) mice were obtained from Charles River Laboratories (Wilmington, MA). Food and
water were given ad libitum. Each animal was kept in individual cages equipped with a HEPA air
filter cover in a light- and temperature-controlled environment. Bilateral PC-3 tumors were
induced by subcutaneous injection of 5.0×106 cells in Matrigel (BD Biosciences). The tumors
were allowed to grow ranging from 0.1 to 1 g (4-6 weeks post-inoculation), before the mice
were utilized in pharmacokinetic studies.
3.2.4 Solid-Phase Peptide Synthesis (SPPS)
Peptide synthesis was performed using an automated solid-phase peptide synthesizer
employing traditional Fmoc chemistry and using a Rink Amide resin. Briefly, the resin (100 µmol
of the resin substituted peptide anchors) was deprotected using piperidine, resulting in the
formation of a primary amine from which the C-terminus of the growing peptide was anchored.
The Fmoc protected amino acids (300 µmol) with appropriate orthogonal protection were
activated with HBTU and sequentially added to the resin. The resulting peptide was orthogonally
deprotected and cleaved from the resin using a cocktail consisting of triisopropyl silane (0.1 mL),
water (0.1 mL), 3,6-dioxa-1,8-octanedithiol (0.1 mL) trifluoroacetic acid (4.625 mL) and
thioanisole (0.075 mL), respectively. The cleaved peptide was subsequently precipitated and
washed using cold (0 °C) methyl-tert-butyl ether (10 mL×3). The crude conjugate was dried by a
centrivap concentrator and weighed. ES-MS was used to determine the molecular mass of the
prepared peptides. All conjugates were peak purified to ≥ 95% purity and quantified by RP-HPLC
prior to in vitro/in vivo investigations.
3.2.5 Coupling of 2-NIAA to Bombesin Conjugates
The 2-NIAA was manually coupled to Ɛ- amino group of the lysine residue for peptides 2*,
3* and 4* (9.2, 29.3 and 16.4 mg respectively) using standard amidation chemistry. Briefly, for
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peptides 2* and 4*, the 2-NIAA (3.6 and 12.1 mg, respectively)/NHS (3.6 and 6.1mg,
respectively) mixtures were dissolved in HBTU/DMF (0.5 M, 83.4 and 142.4 µl) solution followed
by addition of DIEA/NMP solution (5.7 M, 18.1 and 30.9µl). For peptide 3*, the 2-NIAA (16.6
mg)/NHS (11.2 mg) mixtures were dissolved in DCC/DMF (0.9 M, 141.2 µl) solution followed by
addition of DIEA/NMP solution (5.7 M, 56.3 µl). These solutions were allowed to stand for 2 h in
an ice bath before addition of the conjugate in DMF (200 µL). The reaction mixture was stirred
overnight at room temperature and subsequently evaporated to dryness. The residue was redissolved in water : acetonitrile : formic acid (8 : 2 : 0.05), peak purified by RP-HPLC and
characterized by mass spectrometry.
3.2.6 Labeling with natInCl3
For the convenient characterization of the
nat

In was used to substitute for

111

In-Bombesin conjugates, naturally abundant

111

In in the ES-MS and in vitro binding studies. A sample of

conjugates (0.5 mg) was dissolved in ammonium acetate buffer (1 M, 200 μL, pH 5.5) and mixed
with a solution of natInCl3 (5.5 mg, 50 μmol). The solution was heated for 60 min at 50 °C. After
cooling to room temperature,

nat

In-conjugates were then peak purified by RP-HPLC. All

nat

In-

conjugates were ≥ 95% purity before mass spectrometric characterization and in vitro binding
studies were performed.
3.2.7 Radiolabeling with 111InCl3
Radiolabeling was performed on all conjugates by mixing 100 µg samples with 37 MBq
111

InCl3 in ammonium acetate buffer (1 M, 200 μL, pH 5.5). The solution was heated for 60 min at

90 °C. The resulting specific radioactivities were 0.64, 0.71, 0.78 and 0.86 MBq/nmol for 111In-1,
111

In-2,

111

In-3 and

111

In-4. In order to separate radiolabeled peptides from unlabeled peptides

on HPLC, 4-5 mg CoCl2 were then added and incubated for 5 min at 90 °C to increase the

78
hydrophobicity of unlabeled conjugates. The resulting radioconjugates were allowed to cool to
room temperature and peak purified using RP-HPLC (≥95%) and concentrated using C18
extraction disk. Elution of the extraction disk with ethanol/sterile saline solution (6 : 4, 150 μL ×
2) delivered the radioconjugate in high purity. L-ascorbic acid (~20 mg) was added to all
radioconjugates to reduce radiolysis. The specific activities for all peak-purified 111In-conjugates
are essentially the theoretical maximum of 1725 MBq/nmol.
3.2.8 HPLC Purification and Analysis Methodology
When necessary, bulk sample purification was performed using a semi-preparative Proteo
column with a flow rate of 5.0 mL/min. Sample purification for in vitro/in vivo studies was
performed on analytical Proteo column with a flow rate 1.5 mL/min. HPLC solvents consisted of
H2O containing 0.1% formic acid (solvent A) and acetonitrile containing 0.1% formic acid (solvent
B). For all unlabeled and 111/natIn-conjugates, purification was achieved using an initial gradient of
85 % A : 15 % B which linearly decreased to 75 % A : 25 % B over a 15 minute time period. At the
end of the run time, the column was flushed with the gradient 5 % A : 95 % B and reequilibrated to the starting gradient.
3.2.9 In Vitro Competitive Cell-Binding Studies
Briefly, the PC-3 cells (~3×104) were suspended in RPMI 1640 media (pH 7.4, 4.8 mg/mL
HEPES, and 2 mg/mL BSA) and incubated at 4°C for 45 min in the presence of radiolabeled [125ITyr4]-Bombesin and various concentrations of the

nat

In-conjugate. At the end of the incubation

period, the cells were centrifuged, aspirated and washed with media a total of four times. The
cell associated activity was measured using a gamma counter and the IC50 values determined by
nonlinear regression using the one-binding site model of Graphpad PRISM 5 (U.S.).
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3.2.10 In Vitro Internalization and Efflux Studies
Efflux studies were performed using PC-3 cells under normoxic (95% air, 5% CO2) and
hypoxic (94.9% N2, 0.1% O2, 5% CO2) conditions. PC-3 cells were incubated in six-well plates (0.5
× 106 / well) under hypoxic conditions overnight in RPMI 1640 media (pH 7.4, 4.8 mg/mL HEPES,
and 2 mg/mL BSA). On the day of experiment, the cells medium were changed and incubated for
2 h under normoxic and hypoxic conditions, respectively. The cells were then pre-incubated for
2 h at 37°C in the presence of 100,000 cpm of each 111In-radioconjugate. Upon completion of the
incubation, cells were washed thrice with media to discard the unbound peptide. At time points
0, 2, 4 and 8 h, the media was harvest for quantitative analysis as the effluxed ligand. Surface
bound radioactivity was collected by washing the cells twice with an acid wash (50 mM glycineHCl/0.1 M NaCl buffer, pH 2.8). The cells were then lysed at 37°C using a 10 % aqueous SDS
solution and the lyses were collected as internalized ligand. The radioactivity of the effluxed,
surface bounded and internalized fractions for each radioconjugate was determined using a
Multi Viper gamma counter. Statistical analyses were performed by two-way analysis of variance
(ANOVA) using Graphpad PRISM 5 (U.S.).
3.2.11 Cellular Protein Analysis
For the cellular fractionation studies, the procedure for the preparation of normoxic and
hypoxic PC-3 cells (2.5×105 / well) was carried out as outlined in the efflux studies above. On the
day of the experiment, the medium was removed, and the cells were washed with medium and
incubated at 37°C in the presence of 100,000 cpm of each 111In-radioconjugate. At time points 2,
4 and 8 h, the cells were washed thrice with medium to remove the extracellular
radioconjugates and then lysed using 1mL of M-PER at 37°C. The cellular debris was centrifuged
down at 13300×g and the supernatant was then transferred to an Amicon Ultracel 30kDa filter
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device with extra PBS (1mL). The samples were centrifuged at 4000×g for 10 minutes and
washed with PBS (1mL×2). The radioactivity associated with the molecular weight fractions was
collected and determined using a gamma counter.
3.2.12 Pharmacokinetic Studies of 111In-Radioconjugates in PC-3 Xenograft SCID Mice.
Pharmacokinetic studies were carried out using PC-3 tumor bearing SCID mice. The mice
were inoculated with PC-3 cells, and the tumors were allowed to grow ranging from 0.1 to 1 g
(4-6 weeks post-inoculation), before the mice were utilized in pharmacokinetic studies. Each
mouse (average weight, 20 g) received an intravenous bolus via the tail vein of 7.5 µCi (277.5
kBq) of the radio-RP-HPLC peak purified 111In-radioconjugate (111In-1, 111In-2 or 111In-4) in 100 μL
of saline. The mice were sacrificed and their tissues were excised at 1, 4, 24, 48 and 72 h time
points post injection. The excised tissues were weighed, the radioactivity in each tissue was
measured, and the %ID or %ID/g was calculated for each tissue. Blocking Studies were also
investigated on 111In-4 by co-injection with 300 μg of unlabeled conjugate 4 (n=3).
3.2.13 Small Animal SPECT/CT Imaging Studies.
The SPECT g-camera incorporates an array of 5-by-5 solid state cadmium/zinc/telluride (CZT)
modules, each with 1.5-mm (0.06-inch) pixel array of 16 x 16, providing a total of 80 x 80 pixel
array within a field of view of 12.7-cm by 12.7-cm (5-inch by 5-inch). The X-ray detector is
complementary metal oxide semiconductor (CMOS)-based device, having a 2240 X 2368 pixel
matrix with a 50 mm pitch to yield a 12 mm x 12 mm (4.72 inch x 4.72 inch) field of view. The
mice were administered 4~11MBq (0.108~0.300 mCi) of the desired BB2r-targeted peptide in
100 - 200 μL of saline via tail vein injection. At 1, 24, 48 and 72 h post injection, mice were
anesthetized with 1~1.5% isoflurane delivered in a 2:1 mixture of nitrous oxide/oxygen. Image
acquisition was accomplished using a FLEX Triumph X-ray computed tomography/single photon
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emission computed tomography system (CT/SPECT) and software (Gamma Medica, Inc.,
Northridge, CA) fitted with a 5-pinhole (1.0 mm/pinhole) N5F75A10 collimator. 64 SPECT
projections (30 to 90-s acquisition time per projection based on the actual counts) for each
image were acquired using Triumph_SPECT and reconstructed using SpectReconstructionApp.
512 CT projections for each image were acquired and reconstructed using Triumph X-O 4.1. Coregistration of anatomical CT images and functional SPECT was performed using 3D image
visualization and analysis software VIVID, which is based on Amira 4.1.
3.2.14 Statistical Analysis
IC50 values were determined by nonlinear regression using the one-binding site model of
Graphpad PRISM 5. Comparisons of each two groups for efflux studies, cellular protein analysis
studies and biodistribution studies were analyzed by the 2-tailed Student t test, and P value of
less than 0.05 were considered statistically significant.
3.3 RESULTS
3.3.1 Conjugate Synthesis and Radiolabeling
Four radioconjugates were synthesized using the DOTA-X-8-AOC-BBN(7-14)NH2 paradigm
(Figure 3.1). The yields of conjugates 1, 2*, 3* and 4* ranged from 16.67 to 20.44 % as
determined by RP-HPLC. The 2-NIAA coupling of conjugate 2* and 4* were performed by Obenzotriazole-N, N, N’, N’-tetramethyl-uronium-hexafluoro-phosphate (HBTU) conjugation,
whereas conjugate 3* was coupled by using N, N’-Dicyclohexylcarbodiimide (DCC). All attempts
to conjugate 3* with 2-NIAA using HBTU resulted in poor yields (<1%). The products were
purified by RP-HPLC and isolated with yields of 17.4, 26.7 and 19.0 % for conjugates 2, 3 and 4.
RP-HPLC retention time and mass spectrometric identification of the conjugates are listed in
Table 3.1.
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Figure 3.1 Hypoxia enhanced 111In-BB2r-targeted conjugates
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a

3*

2*

1

DOTA-(D)K-(D)K-(D)K-8 AOC–BBN(7-14) NH2

DOTA-(D)K-(D)K-(D)S-8 AOC–BBN(7-14) NH2

DOTA-(D)K-(D)S-(D)S-8 AOC–BBN(7-14) NH2

DOTA-(D)S-(D)S-(D)S-8 AOC–BBN(7-14) NH2

C84H131N25O25S

C85H142N24O20S

C82H135N23O21S

C79H128N22O22S

C76H121N21O23S

Molecular Formula

2117.3

1923.1

1852.2

1811.1

1770.1

1728.9

MS
Calculated

2118.1

1923.9

1852.5

1812.1

1770.8

1729.6

MS
Observed

8.48

14.5

9.32

12.37

7.73

12.08

RP-HPLC
Retention
Time /min

17.1 ± 1.2

12.6 ± 1.4

-

-

-

11.3 ± 1.4

IC50b/nM

Table 3.1 Mass spectrometric and RP-HPLC characterization of conjugates

4*
DOTA [(D)K (2-NIAA)--(D)S-(D)S-8 AOC]–BBN(7-14) NH2

C92H141N29O27S

Analogue

2
DOTA [(D)K (2-NIAA)- (D)K (2-NIAA)-(D)S-8 AOC-BBN(714) NH2

7.1 ± 1.1

3

5.6

7.3 ± 1.1

20.1 ± 1.3
1840.2a

7.87

5.8 ± 1.1

9.87
1839.7

2035.0a

9.2

6.9 ± 1.2

2312
C76H118114InN21O23S

2034.9

2229.5a

10.55

2311.5

C84H128114InN25O25S

2229.1

2423.1a

C100H151N33O29S

C92H138114InN29O27S

2423.3

DOTA [(D)K (2-NIAA)- (D)K (2-NIAA)- (D)K (2-NIAA)-8
AOC] –BBN(7-14) NH2
In-DOTA-(D)S-(D)S-(D)S-8 AOC–BBN(7-14) NH2
In-DOTA [(D)K (2-NIAA)--(D)S-(D)S-8 AOC]–BBN(7-14)
NH2
In-DOTA [(D)K (2-NIAA)- (D)K (2-NIAA)-(D)S-8 AOCBBN(7-14) NH2
In-DOTA [(D)K (2-NIAA)- (D)K (2-NIAA)- (D)K (2-NIAA)-8
AOC] –BBN(7-14) NH2

C100H148114InN33O29S

4
In-1
In-2

In-3

In-4

For convenient mass spectra analysis 111In was replaced by natIn. b Values represent mean ± SEM (n=6)
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3.3.2 In Vitro Competitive Cell-binding Studies
The BB2r binding affinity of the conjugates and

nat

In-conjugates were investigated by

competitive binding studies using the BB2r-positive, PC-3 cell line. All conjugates and
conjugates demonstrated nanomolar binding affinities. The

nat

In-

nat

In-labeled conjugates had IC50

values of 7.1 ± 1.1, 7.3 ± 1.1, 5.8 ± 1.1 and 6.9 ± 1.2 nM for natIn-1-4, respectively. Slightly lower
binding affinities were observed for unlabeled conjugates compared with

nat

In-labeled, but

statistical analysis revealed no overall trend.
3.3.3 In Vitro Internalization and Efflux Studies
We have previously reported that the surface expression of the BB2r remains essentially
unchanged under the hypoxic conditions employed in our studies [145]. In these studies, 111In-1,
which does not have a 2-nitroimidazole incorporated, is the control to compare the relative
effectiveness of the hypoxia trapping conjugates (111In-2-4). The PC-3 cells were first incubated
in the presence of the radioconjugates for 2 h prior to the start of the efflux studies. During this
incubation period, all of the radioconjugates investigated under both normoxic and hypoxic
conditions demonstrated similar levels of internalization, ranging from 18 to 22% of the total
radioactivity added.
The efflux of the radioconjugates over time given as a percentage of the initial internalized
activity is depicted in Figure 3.2. Within the first 2 h of the experiment, the 111In radioconjugates
1-4 under hypoxic conditions demonstrated a lower efflux rate relative to normoxic conditions.
The maximum differences of percentage effluxed radioactivity were observed at 8 h time point
for

111

In-1-4. Specifically, 41.4, 60.7, 69.1 and 69.4 % of initially internalized radioactivity was

retained under hypoxic conditions compared with only 34.8, 35.3, 33.2 and 29.7 % retained
under normoxic conditions, respectively.

111

In-1 also exhibited a significant decrease in
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clearance rate after 2 hours under hypoxic conditions. However, the increased retention
showed by 111In-1 is limited relative to 111In-2-4 which have 2-nitroimidazoles incorporated into
the structure of the radioconjugate. The radioconjugates

111

In-2-4 demonstrated significantly

higher retention under hypoxic conditions relative to normoxic conditions (P<0.0001).
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20%
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6

8
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60%
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0%
0

2

4

6

8

Time (h)

Figure 3.2 Efflux assays for the 111In-radioconjugates in PC-3 cells
Efflux assays depicted as percentage of initial internalized activity for the 111In-radioconjugates
in PC-3 cells. Values are mean ± SD (n=5).
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The internalized activity of the radioconjugate was compared as an additional means of
evaluating the retention effect under normoxic and hypoxic conditions. Hypoxia enhancement
factor (HEF) is defined as the ratio of the amount of activity remaining in the hypoxic cells versus
the normoxic PC-3 cells of radioconjugates internalized. The HEF for each radioconjugate at each
time point is depicted in Figure 3.3. At the initial time point, all of the radioconjugates
demonstrated a similar accumulation under both normoxic and hypoxic conditions where the
HEF is approximately equal to 1. At the 2 h time point, all of the radioconjugates incorporated
with 2-nitroimidazole started to display significantly higher retention in hypoxic relative to
normoxic cells (i.e., HEF > 1). By the 8 h time point, the

111

In-1-4 demonstrated an average HEF

of 1.17 ± 0.12, 1.95 ± 0.28, 2.72 ± 0.35 and 3.29 ± 0.25, respectively. The radioconjugates 111In-24 exhibited significantly higher average HEF ratios than the control. The strong positive linear
relationship between the HEF and the number of 2-nitroimidazoles incorporated was confirmed
by linear regression analysis (R > 0.96).
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HEF: hypoxic/normoxic
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Figure 3.3 HEF ratios for the efflux studies of 111In-BB2r-targeted radioconjugates
HEF ratios for the efflux studies of 111In-BB2r-targeted radioconjugates under normoxic (95%
air, 5% CO2) and hypoxic conditions (94.9% N2, 0.1% O2, 5% CO2). Values are mean ± SD (n=5).
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3.3.4 Cellular Protein Analysis
It is well established that 2-nitroimidazoles are reductively-activated in a hypoxic
environment. This activation leads to the irreversible conjugation of the reduced 2nitroimidazole moiety with intracellular nucleophiles (e.g., thiols), including those contained in
proteins, to form adducts [131, 146, 147]. In order to better elucidate the mechanism of the
observed increase in retention of the 2-nitroimidazole containing BB2r-targeted agents under
hypoxic conditions, the protein association properties of the conjugates were evaluated under
hypoxic and normoxic environments. At the 2, 4 and 8 h post incubation time points, the PC-3
cells were lysed and centrifuged. The supernatant was then filtered using a 30 kDa centrifugal
filter. The ratio of protein associated radioactivity as a percentage of total intracellular
radioactivities under hypoxic conditions over the percentage of protein associated radioactivity
under a normoxic environment is depicted in Figure 3.4. The control radioconjugates

111

In-1

demonstrated similar ratios, from 1.08 to 1.38, during the timespan of the experiment. The 2nitroimidazole containing BB2r-targeted conjugates demonstrated at least one fold higher
protein association under hypoxic conditions than that observed under normoxic conditions. For
111

In-4, at 4 and 8 h time points, up to three fold higher hypoxic/normoxic protein association

ratios were observed relative to the control. These results strongly suggest that 2nitroimidazoles are partially responsible for this enhancement.
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Hypoxic-to-normoxic ratio

4.00

¹¹¹In-1
¹¹¹In-2

3.00

¹¹¹In-3
¹¹¹In-4

2.00

1.00

0.00
2

4

8

Time (h)
Figure 3.4 Protein association studies
Protein association studies under normoxic (95% air, 5% CO2) and hypoxic (94.9% N2, 0.1% O2,
5% CO2) conditions in PC-3 cells. Values are mean ± SD (n=5).
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3.3.5 Biodistribution studies
The in vivo biodistribution of the

111

In-1,

111

In-2 and

111

In-4 radioconjugates were

investigated in PC-3 tumor bearing SCID mice. Due to the similar efflux and protein association
properties of

111

In-3 and

111

In-4,

111

In-3 was not investigated in vivo. The results obtained from

pharmacokinetic studies of 111In-1, 111In-2 and 111In-4 at 1, 4, 24, 48 and 72 h p.i. are summarized
in Table 3.2. All of the investigated 111In-radioconjugates demonstrated rapid blood clearance at
1 h post injection. Clearance of the radioconjugates proceeded largely through the renal/urinary
system. At 1 h post injection, the highest accumulation was found in the pancreas for all three
radioconjugates with 70.96 ± 15.88, 33.70 ± 27.11 and 33.04 ± 19.50 %ID/g, respectively. These
results are due to the high expression of BB2r in rodent pancreas and are consistent with
previous reports [148, 149]. The tumor retention of radioconjugate 111In-4 (2.80 ± 1.18 %ID/g) at
1 h p.i. is substantially lower than

111

In-1 (5.82 ± 2.63%ID/g) and

111

In-2 (6.06 ± 3.35%ID/g).

However, by the 72 h post injection time point, 1.5%, 6.7% and 21.0% of the initial 1 h uptake
was retained in the tumor tissue corresponding to radioconjugates

111

In-1,

111

In-2 and

111

In-4

(Figure 3.5). The tumor retention observed for both 111In-2 (0.41 ± 0.07 %ID/g, P<0.01) and 111In4 (0.60 ± 0.40 %ID/g, P<0.05) was found to be significantly higher as compare with the control
111

In-1 (0.09 ± 0.10 %ID/g). With the exception of the kidneys, the addition of the 2-

nitroimidazoles did not increase the non-target retention of the BB2r-targeted agents. The initial
kidney uptake for all of the radioconjugates investigated was approximately 15 %ID/g at the 1 h
time point. By 72 h post injection the conjugates

111

In-2 (2.66 ± 0.73 %ID/g) and

111

In-4 (8.83 ±

5.69 %ID/g) demonstrated significant retention (P<0.05) in the kidneys as compared to

111

In-1

(0.76 ± 0.67 %ID/g). In this study, the kidney retention correlated with an increase in the 2nitroimidazole moieties of the BB2r-targeted agent. The co-injection of an excess of unlabeled
conjugate 4 along with 111In-4 resulted in significantly reduced radioactivity in the pancreas (1.16
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± 0.66 %ID/g), kidney (12.37 ± 7.92 %ID/g) and tumor (0.44 ± 0.34 %ID/g) at 4 h post injection
(P<0.05, one-tailed).
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Table 3.2 Biodistribution Studies in PC-3 Tumor-Bearing SCID micea
Tissue (%ID/g)
1 h p.i.
4 h p.i.
24 h p.i.
48 h p.i.
111
In-1
blood
0.11 ± 0.22
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
heart
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
lung
0.21 ± 0.40
0.02 ± 0.03
0.00 ± 0.00
0.00 ± 0.00
liver
0.40 ±0.32
0.09 ± 0.11
0.03 ± 0.03
0.00 ± 0.00
pancreas
70.96 ± 15.88 37.17 ± 10.52 12.07 ± 3.05
6.51 ± 2.26
stomach
5.87 ±3.63
1.02 ± 0.72
0.34 ± 0.26
0.11 ± 0.23
small intestine
8.15 ±2.93
2.04 ± 0.59
0.96 ± 0.52
0.66 ± 0.18
(%ID)
large intestine
5.07 ±1.26
4.74 ± 2.08
1.62 ± 0.54
1.71 ± 0.87
(%ID)
kidney
13.41 ± 5.84
4.82 ± 1.60
2.18 ± 0.67
1.38 ± 1.01
tumor
5.82 ±2.63
2.16 ± 1.01
1.32 ± 0.62
0.83 ± 0.48
muscle
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
bone
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
brain
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
excretionb (%ID ) 35.88 ± 14.38 82.06 ± 4.65
91.07 ± 1.75 93.42 ± 3.26
111
In-2
blood
1.21 ± 0.61
0.00 ± 0.00
0.02 ± 0.02
0.00 ± 0.00
heart
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
lung
1.21 ± 0.98
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
liver
0.87 ± 0.38
0.15 ± 0.05
0.13 ± 0.05
0.08 ± 0.01
pancreas
33.70 ± 27.11 14.01 ± 13.97
1.98 ± 1.35
0.25 ± 0.17
stomach
1.51 ± 1.69
0.49 ± 0.20
0.06 ± 0.08
0.07 ± 0.09
small intestine
4.62 ± 1.42
1.44 ± 0.61
0.23 ± 0.10
0.12 ± 0.06
(%ID)
large intestine
2.02 ± 0.7
3.82 ± 1.11
0.57 ± 0.18
0.35 ± 0.14
(%ID)
kidney
14.88 ± 4.55
5.09 ± 1.70
3.74 ± 1.65
2.03 ± 0.42
tumor
6.06 ± 3.35
1.89 ± 0.92
1.08 ± 0.49
0.58 ± 0.24
muscle
1.69 ± 1.72
0.12 ± 0.25
0.00 ± 0.00
0.00 ± 0.00
bone
0.71 ± 0.42
0.14 ± 0.15
0.00 ± 0.00
0.00 ± 0.00
brain
0.02 ± 0.05
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
b
excretion (%ID)
17.26 ± 15.53 81.24 ± 8.28
94.89 ± 0.67 96.10 ± 0.61

72 h p.i.
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
0.02 ± 0.04
0.46 ± 0.28
0.76 ± 0.67
0.09 ± 0.10
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
98.44 ± 0.48
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
0.06 ± 0.02
0.22 ± 0.12
0.04 ± 0.08
0.02 ± 0.02
0.15 ± 0.04
2.66 ± 0.73
0.41 ± 0.07
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
95.90 ± 0.95
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Table 3.2 (continued) Biodistribution Studies in PC-3 Tumor-Bearing SCID micea
Tissue (%ID/g)
1 h p.i.
4 h p.i.
24 h p.i.
48 h p.i.
72 h p.i.
111
In-4
blood
0.75 ± 0.54
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
heart
0.73 ± 1.46
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
lung
0.61 ± 1.04
0.41 ± 0.82
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
liver
0.38 ± 0.36
0.30 ± 0.24
0.20 ± 0.45
0.45 ± 0.33
0.01 ± 0.02
pancreas
33.04 ± 19.50 7.73 ± 2.70
0.62 ± 1.25
0.06 ± 0.12
0.00 ± 0.00
stomach
0.50 ± 0.75
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
small intestine
3.18 ± 1.77
1.00 ± 0.59
0.25 ± 0.18
0.01 ± 0.01
0.09 ± 0.14
(%ID)
large intestine
2.16 ± 0.94
2.38 ± 1.05
0.83 ± 0.16
0.57 ± 0.33
0.24 ± 0.27
(%ID)
kidney
17.90 ± 10.88 25.79 ± 4.66 23.40 ± 12.33 12.87 ± 2.76 8.83 ± 5.69
tumor
2.80 ± 1.18
1.43 ± 0.62
0.92 ± 0.46
0.69 ± 0.53
0.60 ± 0.40
muscle
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
bone
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
brain
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
excretionb (%ID)
61.95 ± 23.27 80.86 ± 2.63 87.21 ± 2.75 91.55 ± 1.73 93.85 ± 2.78
a

Organ uptake values expressed as %ID/g and values are mean ± SD (n=4) unless otherwise noted.
Excretion values were calculated using the activity values associated with the excreted urine, bladder,
and fecal material contents at the time of sacrifice.
b
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Figure 3.5 Percentage tumor retention of 111In-radioconjugates
Percentage tumor retention of
Values are mean ± SEM (n=4).

111

In-1,

111

In-2 and

111

In-4 in PC-3 tumor-bearing SCID mice.
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3.3.6 Small Animal SPECT/CT Imaging Studies
Small animal SPECT/CT Imaging studies were performed in PC-3 tumor bearing SCID mice
using the 111In-1, 111In-2, and 111In-4 radioconjugates. The whole body images and the respective
axial slices of the PC-3 tumors at 1, 24, 48 and 72 h p.i. are depicted in Figure 3.6. At 1 h post
injection, significant abdominal uptake was observed in all cases due to the accumulation of
radioactivity in the G.I. tract and pancreas as previously demonstrated in the biodistribution
studies. Axial slices of the PC-3 tumor for all the radioconjugates investigated exhibited
substantial accumulation of radioactivity in the tumor tissue after the rapid clearance of the
radioconjugates through the renal/urinary system. For

111

In-4 radioconjugates, conspicuous

kidney retention is observed, echoing the biodistribution studies.
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Figure 3.6 Fused micro SPECT/CT and axial images
Fused micro SPECT/CT and axial images of

111

In-1,

111

In-2 and

111

In-4 in PC-3 tumor-bearing

mice at 1, 24, 48 and 72 h after injection. Tumors and kidneys are indicated by red and green
arrows respectively.
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3.4 DISCUSSION
To determine if the incorporation of 2-nitroimidazoles would increase the retention of the
radioconjugate in hypoxic PC-3 cells, we have previously synthesized four BB2r-targeted agents,
that included 2-nitroimidazole moieties [145]. In vitro studies showed improved longitudinal
retention of the 2-nitroimidazole containing BB2r-targeted agents in hypoxic relative to
normoxic PC-3 cells. However, it was determined that the steric interference of the 2nitroimidazole with the BB2r-targeting vector resulted in poor binding affinities which severely
impeded internalization of these conjugates. In this study, an extended linker (8-AOC) was
incorporated between the 2-nitroimidazole-amino acid residue and the pharmacophore. The
BB2r affinities of (1-4) natural indium labeled and unlabeled conjugates versus [125I-Tyr4] BBN
were performed for the GRP receptor using the PC-3 cell line. All

nat

In-BBN conjugates

demonstrated nanomolar binding affinity. Based on these results, the incorporation of the 8AOC linker has eliminated the detrimental impact of 2-NIAA side chain on pharmacophore
binding.
Internalization and efflux studies demonstrated that the clearance rate of the
radioconjugates containing 2-nitroimidazole was substantially lower relative to the control
under hypoxic conditions. Specifically, 6.6, 25.4, 35.9 and 39.7% more retention were observed
at the 8 h time point for 111In-1-4 under hypoxic conditions relative to normoxic conditions. 111In3 and

111

In-4 which have more than one 2-nitroimidazoles (2 and 3, respectively) exhibited a

higher retention effect than 111In-2 which has only one 2-nitroimidazole. Inclusion of more than
one hypoxia trapping moiety may increase the chances for the 2-nitroimidazole containing
radioconjugates to form protein adducts thus enhancing the long-term retention of the
radioconjugate in the cell. Ultimately, further investigation into the identification and
quantification of the protein-adduct is needed to obtain a clearer understanding of the
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mechanism involved in this process. It was also interesting to note that,

111

In-1 exhibited a

slightly lower clearance rate under hypoxic conditions, which could be due to the decreased
metabolic rate under hypoxic conditions [105]. With respect to the hypoxia enhancement factor,
significantly higher retention in hypoxic relative to normoxic cells was observed for
the 2 h time point. The HEF continued to increase for
experiments, but remained constant for

111

In-3 and

111

In-1 and

111

In-2-4 at

111

In-2 throughout the

111

In-4 after the 4 h time point. A strong

positive linear relationship between the HEF and the number of 2-nitroimidazoles incorporated
was confirmed for the 8 h time points.
Cellular protein analysis of the control radioconjugate

111

In-1 demonstrated minimal

hypoxic/normoxic cellular protein association ratios which are likely due to reversible,
nonspecific binding. For the 2-nitroimidazole containing BB2r-targeted conjugates, up to a 2 fold
increase was observed under hypoxic conditions. These results suggest that the significantly
higher protein association ratio of 2-nitroimidazole containing radioconjugates is due, at least in
part, to the irreversible binding to intracellular proteins which is consistent with the known
trapping mechanism of 2-nitroimidazole.
The in vivo biodistribution of each radioconjugate was investigated in PC-3 tumor bearing
SCID mice, except for 111In-3 due to the similar efflux and protein association properties as 111In4. At 1 h post injection,

111

In-1 and

111

In-2 share comparable tumor uptake, 5.82 ± 2.63 %ID/g

and 6.06 ± 3.35 %ID/g, respectively. However, a substantially lower tumor uptake (2.80 ± 1.18
%ID/g) was observed for
similar uptake of

111

111

In-4 which has three 2-nitroimidazoles incorporated. Given the

In-2 and

111

In-4 in the BB2r-positive pancreas, the reason behind the

reduced tumor uptake is unclear. At 4 h post injection, most of the radioconjugates were
cleared through the renal/urinary system (80 - 82 %ID) which is consistent with other
investigations of BB2r- targeted radioconjugates [149]. By the 72 h post injection time point, the
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radioconjugates were largely cleared from most tissues, including the pancreas [150]. Significant
111

tumor retention enhancement was observed at 72 h post injection for radioconjugates

In-2

and 111In-4. Specifically, 6.7% and 21.0% of the initial 1h uptake in tumor was retained for 111In-2
and

111

In-4, compared with only 1.5% remaining for the control

111

In-1. However, the hypoxia

burden of each tumor is unknown which limits the ability to fully interpret the relationship
between tumor retention effect and incorporation of the hypoxia trapping moiety. The hypoxia
burden in tumor xenograft mouse models has been shown to increase (modest correlation) with
an increase in tumor size, but this trend is highly dependent on the cell-line [151]. Linear
regression analysis of the %ID/g retention of our radioconjugates in PC-3 tumors versus tumor
weight revealed no correlation between retention and tumor size. Interestingly, in the clinic, the
extent of hypoxia is independent of tumor size in a variety of human cancer including head and
neck, cervix and lung cancer [152-154]. Further study to correlate the tumor hypoxia burden
with radioconjugate retention is ongoing. Significantly lower tumor and pancreas uptake caused
by co-injection of an excess of unlabeled conjugate 4 indicates that accumulation of

111

In-4 is

largely mediated by the BB2r.
It is interesting to note the unusually high kidney retention for 2-nitroimidazole containing
conjugates relative to the control conjugate. Especially for

111

In-4, up to 8.83 ± 5.69 % ID/g in

kidney was observed at 72 h post injection, information which has not been reported in any
research related to BBN or 2-nitroimidazole based radioconjugates [148, 149, 155, 156]. Renal
retention of radiolabeled targeting peptide has long been addressed as one of the dose-limiting
factors in radionuclide therapy and various mechanisms have been demonstrated to be involved
in high renal uptake [157]. Cationic peptides are preferentially reabsorbed by the proximal
tubules due to the anionic binding sites on the brush border membrane [158, 159]. Megalin and
cubilin are known to be associated with the proximal tubular reabsorption of structurally
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different proteins, peptides, and drugs [160]. Moreover, low or very low tissue oxygen tensions
exist under physiologic conditions in kidneys, which facilitates urine concentration [161]. Coinfusion of competitive inhibitors such as lysine, arginine and succinylated gelatin can reduce
the reabsorption by endocytosis or transporters [162-164]. In preliminary co-injection blocking
studies (data not shown), both EF5 (a 2-nitroimidazole based hypoxia marker) and lysine coinjection with 111In-4 can reduce the retention of radioconjugates in kidney. Further studies are
needed to fully understand the mechanism of kidney retention of hypoxia trapping enhanced
BBN conjugates in order to develop specific methods to reduce the renal toxicity.
MicroSPET/CT images of all radioconjugates using PC-3 tumor-bearing mice at 1 h post
injection (Fig. 6), showing significant abdominal uptake, are consistent with the data obtained
from biodistribution studies. The PC-3 tumor xenografts in all mice are easily visualized. For the
111

In-4 radioconjugates, containing three 2-nitromididazoles, significant activity in kidneys was

observed which strongly agrees with previously established biodistribution data.
3.5 CONCLUSION
We have synthesized three BB2r-targeted radioconjugates with 2-nitroimidazole hypoxia
trapping moieties incorporated to enhance the retention in hypoxic cancer cells. In vitro
competitive binding studies indicate that inclusion of extended linker 8-AOC eliminated the
detrimental effect on binding affinity that was determined in our previous report. The 2nitroimidazole trapping moieties containing BB2r-targeted agents demonstrated significant
higher retention and protein association properties in hypoxic relative to normoxic PC-3 cells. In
vivo biodistribution studies revealed great potential of incorporated trapping moieties to
increase the residence time of BB2r-targeted agents in PC-3 xenograft tumor. Further works are
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needed to clarify the mechanisms of increased retention effects at the molecular level and to
correlate the tumor hypoxia burden with the retention efficacy.
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Chapter 4 Synthesis, Radiochemical Stability and In Vitro Investigation of a New Series of
Nitroimidazole Incorporated 177Lu-labeled Bombesin Analogs
4.1 INTRODUCTION
As mentioned in previous chapters, our observations to date seem to be consistent with this
proposed mechanism of action with the 2-nitroimidazole incorporated BB2r-targeted agents
exhibiting a prolonged retention in hypoxic prostate cancer cells and a resultant increase in the
association with intracellular proteins [165].
In this report, we continue to explore the development of hypoxia-enhanced BB2r-targeted
agents. Specifically, we synthesize a new series of hypoxia-enhanced BB2r-targeted agents,
depicted in Figure 4.1, with 0, 1, 3 and 5 2-nitroimidazoles. In addition, the design includes a
polyethylene glycol linker to increase the hydrophilicity of the resulting BB2r-targeted agents.
With these analogs in hand, we further explore the effect oxygen concentrations have on the
retention of the hypoxia-enhanced BB2r-targeted agents in human prostate cancer cells.
Furthermore, with previously analoged series (not reported), we observed significantly
increased rates of radiolysis with 2-nitroimidazole incorporated BB2r-targeted agents relative to
controls (absence of 2-nitroimidazoles)[165]. Herein, we additionally describe the use of
radioprotectants to increase the longevity of the prepared hypoxia-enhanced BB2r-targeted
agents for future use.
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Figure 4.1 Hypoxia enhanced 177Lu-BB2r-targeted conjugates
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4.2 MATERIALS AND METHODS
4.2.1 Chemical and Supplies
Unless otherwise noted all solvents were used without further purification. Deionized water
was purified by a Millipore (U.S.) Mili-Q-Biocel. Acetonitrile, formic acid, N, Ndiisopropylethylamine (DIEA), N,N-dimethylformamide (DMF), dichloromethane (DCM), Nmethylpyrrolidone

(NMP),

N-Hydroxysuccinimide

(NHS),

1-Ethyl-3-(3-

dimethylaminopropyl)carbodiimide hydrochloride (EDC), thioanisol, sodium hydroxide, Lascorbic acid, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), bovine serum
albumin (BSA) and sodium dodecyl sulfate (SDS) were purchased from Fisher Scientific (U.S.). 2nitroimidazole was purchased from Amfinecom (U.S.). 2-nitroimidazole acetic acid (2-NIAA) was
synthesized as reported earlier. O-Benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluorophosphate (HBTU), F moc-NH-PEG3-COOH, Fmoc-protected natural amino acids and the
appropriate Rink Amide resins were purchased from Nova Biochem (U.S.). Fmoc-D-lys-OH
ydrochloride was purchased from CreoSalus (U.S). Roswell Park Memorial Institute (RPMI) 1640
media and phosphate buffered saline (PBS) were purchased from Thermo Scientific (U.S.).
Naturally abundant lutietium chloride (natLuCl3), triisopropyl silane, trimethylsilyl chloride,
hydrochloric acid (HCl) and 3, 6-dioxa-1, 8-octanedithiol were purchased from Sigma-Aldrich
(U.S.). The [125I-Tyr4]-bombesin and lutietium-177 chloride (177LuCl3) were purchased from Perkin
Elmer (U.S.). The human prostate cancer cell line, PC-3, was obtained from American Type
Culture Collection (U.S.) and cultured under vendor recommended conditions. TrypLETM Express
was purchased from Invitrogen (U.S.).
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4.2.2 Equipment
The peptides were synthesized on a Liberty microwave peptide synthesizer from CEM (U.S.).
HPLC/MS analyses were performed on a Waters (U.S.) e2695 system equipped with a Waters
2489 absorption detector and a Waters Qtof Micro electrospray ionization mass spectrometer.
Evaluation and purification of radiolabeled conjugates was performed on a Waters 1515 binary
pump equipped with a Waters 2489 absorption detector and a Bioscan (U.S.) Flow Count
radiometric detector system. A Phenomenex (U.S.) Jupiter 10µ Proteo 250 × 10 mm semiprep
column was used for the purification of bulk amounts of peptides. The peptides were
concentrated on a Centrivap (U.S.) Centrifugal Concentrator. For the purification of conjugates,
nat

Lu-conjugates, and

177

Lu-radioconjugates a Phenomenex Jupiter 10µ Proteo 250 × 4.60 mm

analytical column was employed. Solid phase extraction was performed using 3M Empore (U.S.)
C18 10 mm high performance extraction disks. Nuclear magnetic resonance spectra were
recorded on Varian (U.S.) 500MHz INOVA spectrometer. 1H NMR chemical shifts are expressed
as δ values (parts per million) and peaks are described as s for singlet and d for doublet. Hypoxic
PC-3 cells were incubated in a hypoxic glove box with temperature, CO2 and humidity controller
(Coy Laboratory, U.S.). Gamma decay detection of

177

Lu and

125

I for the in vitro binding, efflux

studies was accomplished using a LTI (U.S.) Multi-Wiper nuclear medicine gamma counter.
4.2.3 Synthesis of Methyl (((9H-fluoren-9-yl)methoxy)carbonyl)-D-lysinate Hydrochloride,
Compound I
The synthesis of compound I followed the procedure described earlier. Briefly, Fmoc-Dlysine hydrochloride (500 mg, 1.2 mmol) was placed in a 25ml round bottomed flask with a
magnetic stirrer and dissolved in anhydrous methanol (10 ml). To this solution, trimethylsilyl
chloride (0.6 ml, 6 mmol) was added and the reaction was stirred at room temperature for 36 h.
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The solvent was evaporated to dryness to yield a yellow oil. Anhydrous diethyl ether (20 ml) was
added to the oil which precipitated a white solid (compound I) after 15 min of stirring. The
resulting mixture was filtered and washed with ether (2×5 ml) to give Fmoc-D-lys methyl ester
hydrochloride with 98% yield (506 mg). 1H NMR 1H (DMSO): δ 8.16 (s, 2H ,NH2)7.87 (d, A FMOC
)7.83 (t, D FMOC) 7.41 (t B FMOC) 7.32 (t, C FMOC) 4.27( s,1H ,NH) ,4.29 ( d ,F CH2 FMOC) ,4.25(
t, E CH FMOC ), 3.60 (s, 3H,CH3),3.43 (s, 2H ,CH2),1.65-156 (m, 4H CH2- CH2), 2.72 (s, 2H ,CH2),
1.36 (d, 1H ,CH).

13

C NMR (DMSO): 172.89 (C=O Ester ), 156.18 (C=O NH), 143.78 (G, C

benzene)140.75 (H,C benzene),127.67 (C-C benzene) 127.09 (B, C benzene),125.27 (A, C
benzene),120.15 (D, C benzene),65.63 (F,C aliphatic), 53.75(M, C aliphatic) , 51.92 (N, C
aliphatic), 46.66 (E, C benzene ), 38.33 (I, C aliphatic), 30.54( K, C aliphatic) 26.38 (J, C aliphatic)
22.47 (L, C aliphatic). MS (ESI): m/z calculated for C22H26N2O4:382.189. Found (m/z, [M +
H+]):383.092.
4.2.4 Synthesis of Methyl N2-(((9H-fluoren-9-yl)methoxy)carbonyl)-N6-(2-(2-nitro-1H-imidazol1-yl)acetyl)-D-lysinate, Compound II
Compound II was synthesized using established amidation chemistry. Briefly, 2-NIAA (58 mg,
0.31 mmol), NHS (110 mg, 0.93 mmol) and EDC (178 mg, 0.93mmol) were added to a 25 ml
round bottom flask with stir bar and dissolved in DMF (20 mL). The solution was allowed to
stand for 2 h in an ice bath. Compound I (130 mg. 0.31mmol) was added to the solution and
stirred overnight at room temperature. The volume of the DMF solution was reduced to 10 mL
and the remaining solution was purified by semi-preparative RP-HPLC. HPLC solvents consisted
of H2O containing 0.1% formic acid (solvent A) and acetonitrile containing 0.1% formic acid
(solvent B). Solvent A and B were used for all RP-HPLC method described in this paper unless
mentioned elsewhere. For purification of compound II, an initial gradient of 70 % A : 30 % B
linearly decreased to 75 % A : 25 % B over a 15 minute time period. At the end of the run time
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for all HPLC experiments, the column was flushed with the gradient 5 % A : 95 % B and reequilibrated to the starting gradient. 1H NMR 1H (DMSO): δ 8.31 (s, 2H ,NH2)7.89 (d, A FMOC
)7.87 (t, D FMOC) 7.71 (1H, d, imidazole ring) ,7.53 (1H, d, imidazole ring) ,7.41 (t, B FMOC) 7.31
(t, C FMOC),5.05 (2H, s, NCH2COO), 4.30( s,1H ,NH) ,4.29 ( d ,F ,CH2, FMOC) ,4.22( t E,CH FMOC ),
3.61 (s, 3H,CH3),3.39 (s, 2H ,CH2), 3.07 (s, 2H ,CH2), 1.69-1.57 (m, 4H CH2- CH2),1.41-1.31 (d, 1H
,CH).

13

C NMR (DMSO): 172.98(C=O Ester ),165.39 (NO2-C imidazole ring ) 156.18 (C=O NH),

143.82 (G, C benzene)140.77 (H,C benzene),128.80 (CH-imidazaole ring), 127.69 (CH-imidazole
ring), 127.45 (C-C benzene) 127.11 (B, C benzene),125.26 (A, C benzene),120.16 (D, C
benzene),65.65 (F,C aliphatic), 53.82M, C aliphatic) , 51.89 (N, C aliphatic), 46.68 (NCH2), 40.0 (E,
C benzene ), 30.32 (I, C aliphatic), 30.54( K, C aliphatic) 28.51 (J, C aliphatic) 22.83 (L, C aliphatic).
MS (ESI): m/z calculated for C27H29N5O7:535.207. Found (m/z, [M + H+]):536.147.
4.2.5 Synthesis of N2-(((9H-fluoren-9-yl)methoxy)carbonyl)-N6-(2-(2-nitro-1H-imidazol-1yl)acetyl)-D-lysine, Compound III
The methyl ester on compound II was taken off by hydrolysis with HCl. The hydrolysis
process was monitored by HPLC. Briefly, compound II (100 mg, 0.2 mmol) was dissolved in 50 ml
acetonitrile and excess amount of concentrated HCl was added. The conversion of methyl ester
to carboxylic acid was monitored by RP-HPLC using the same gradient for compound II. When
100% conversion ratio (UV-314nm) was achieved, the solutions were neutralized by sodium
carbonate and the final product compound III was extracted by methanol The resulting solutions
were concentrated and peak purified by HPLC. 1H NMR 1H (DMSO): δ 8.32 (s, 2H ,NH2) 7.88 (d,
A FMOC )7.86 (d, D FMOC) 7.72(1H, d, imidazole ring) ,7.53 (1H, d, imidazole ring) ,7.41 (t, B
FMOC) 7.33 (t, C FMOC),5.05 (2H, s, NCH2COO), 4.27( s,1H ,NH) ,4.25 ( d ,F CH2, FMOC) ,4.22( t E
CH FMOC ), 3.43 (s, 2H ,CH2),1.69-1.57 (m, 4H CH2- CH2), 3.07 (s, 2H ,CH2), 1.39-1.33 (d, 1H
,CH).

13

C NMR (DMSO): 174.17(C=O Ester ),165.34 (NO2-C imidazole ring ) 156.18 (C=O NH),
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143.83 (G, C benzene) 140.73 (H,C benzene),128.78 (CH-imidazaole ring), 127.65 (CH-imidazole
ring), 127.42 (C-C benzene) 127.09 (B, C benzene),125.31 (A, C benzene),120.13 (D, C
benzene),65.57 (F,C aliphatic), 53.92(M, C aliphatic) , 51.57 (N, C aliphatic), 46.68 (NCH2), 40.12
(E, C benzene ), 38.65 (I, C aliphatic), 22.99 (L, C aliphatic). MS (ESI): m/z calculated for
C26H27N5O7:521.191. Found (m/z, [M + H+]):522.121.
4.2.6 X-ray Crystallization of Compound II
X-ray Crystallographic Analysis: Single crystals of the compound II were grown from a
mixture of water : methylene dichloride : hexane (1 : 1 : 0.5) solution by slow evaporation. A
suitable crystal was selected and mounted on a Cryoloop and placed on an Xcalibur, Onyx, Ultra
diffractometer. The crystal was kept at 100 K during data collection. Using Olex2, the structure
was solved with the XS structure solution program using Direct Methods and refined with the XL
refinement package using Least Squares minimization.
Crystal data for compound II C27H29N5O7 (M =535.55): monoclinic, space group P21 (no. 4),
a = 4.88855(9) Å, b = 15.3693(3) Å, c = 17.7026(4) Å, β = 96.630(2)°, V = 1321.16(5) Å3, Z = 2, T =
100 K, μ(Cu Kα) = 0.823 mm-1, Dcalc = 1.346 g/mm3, 11238 reflections measured (7.64 ≤ 2Θ ≤
153.58), 5302 unique (Rint = 0.0474) which were used in all calculations. The final R1 was 0.0403
(>2sigma(I)) and wR2 was 0.1119 (all data) with GOF= 1.082. Crystallographic data for the
structural analysis has been deposited with the Cambridge Crystallographic Data Center (CCDC
838909). Copies of this information may be obtained free of charge from the CCDC (www:
http://www.ccdc.cam.ac.uk) or from e-mail jcgarrison@unmc.edu
4.2.7 Solid-Phase Peptide Synthesis (SPPS)
Peptide synthesis was performed using an automated solid-phase peptide synthesizer
employing traditional Fmoc chemistry and using a Rink Amide resin. Briefly, the resin (100 µmol
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of the resin substituted peptide anchors) was deprotected using piperidine, resulting in the
formation of a primary amine from which the C-terminus of the growing peptide was anchored.
The Fmoc protected amino acids (300 µmol) with appropriate orthogonal protection were
activated with HBTU and sequentially added to the resin. The resulting peptide 0, 1*, 2* and 3
was orthogonally deprotected and cleaved from the resin using a cocktail consisting of
triisopropylsilane (0.1 mL), water (0.1 mL), 3,6-dioxa-1,8-octanedithiol (0.1 mL), trifluoroacetic
acid (4.625 mL) and thioanisole (0.075 mL). The cleaved peptide was subsequently precipitated
and washed using cold (0 °C) methyl-tert-butyl ether (40 mL×3). The crude conjugate was dried
by a centrivap concentrator and weighed. ES-MS was used to determine the molecular mass of
the prepared peptides. All conjugates were peak purified to ≥ 95% purity and quantified by RPHPLC prior to in vitro investigations. For conjugates 0 and 1*, an initial gradient of 85 % A : 15 %
B linearly decreased to 75 % A : 25 % B over a 15 minute time period. For conjugates 2*, an
initial gradient of 80 % A : 20 % B linearly decreased to 70 % A : 30 % B over a 15 minute time
period. For conjugates 3, an initial gradient of 75 % A : 25 % B linearly decreased to 65 % A : 35
% B over a 15 minute time period. At the end of the run time for all HPLC experiments, the
column was flushed with the gradient 5 % A : 95 % B and re-equilibrated to the starting gradient.
4.2.8 Coupling of 2-NIAA to Bombesin Conjugates
The 2-NIAA was manually coupled to Ɛ-amino group of the lysine residue for peptides 1* (20
mg, 9.8 µmol) and 2* (20 mg, 9.4 µmol) using established amidation chemistry. Briefly, for
peptides 1* and 2*, the 2-NIAA (1.8 mg, 10.7 µmol and 5.3 mg, 30.9 µmol, respectively), NHS
(3.4 mg, 29.2 µmol and 10.8 mg, 93.8 µmol, respectively) and EDC (5.6 mg, 29.2 µmol and 17.9
mg, 93.9 µmol) mixtures were dissolved in DMF (200 µL). These solutions were allowed to stand
for 2 h in an ice bath before addition of the conjugate 1* and 2* in DMF (200 µL). The reaction
mixture was stirred overnight at room temperature and subsequently evaporated to dryness.
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The residue was re-dissolved in water : acetonitrile (8 : 2), peak purified by semi-preparative RPHPLC and characterized by mass spectrometry.
4.2.9 Labeling with natLuCl3
177

For the convenient characterization of the

Lu-Bombesin conjugates, naturally abundant

nat

Lu was substituted for 177Lu in the ES-MS and in vitro binding studies. A sample of conjugates

(1 mg) was dissolved in ammonium acetate buffer (0.5 M, 200 μL, pH 5.5) and mixed with a
solution of natLuCl3 (4-5 mg). The solution was heated for 30 min at 50 °C. After cooling to room
temperature,

nat

Lu-conjugates were then peak purified by RP-HPLC. All

nat

Lu-conjugates were ≥

95% purity before mass spectrometric characterization and in vitro binding studies were
performed.
4.2.10 Radiolabeling with 177LuCl3
Radiolabeling was performed on all conjugates by mixing 25 µg samples with 37 MBq
177

LuCl3 in ammonium acetate buffer (0.5 M, 120 μL, pH 5.5). The solution was heated for 60 min

at 90 °C and allowed to cool to room temperature. The resulting specific activities were 3.23,
3.52, 4.09 and 4.67 MBq/nmol for

177

Lu-0,

177

Lu-1,

177

Lu-2 and

177

Lu-3. In order to separate

radiolabeled peptides from unlabeled peptides on HPLC, 4-5 mg CoCl2 was then added and
incubated for 5 min at 90 °C to increase the hydrophobicity of unlabeled conjugates. The
resulting radioconjugates were peak purified using RP-HPLC (≥95%) and concentrated using C18
extraction disk. Elution of the extraction disk with ethanol/sterile saline solution (6:4, 200 μL)
delivered the radioconjugates in high purity. A 200 μl solution of selemethionine (0.20mg/ml)
and ascorbic acid (40mg/ml) in 90% PBS buffer was added to all radioconjugates to reduce
radiolysis.
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4.2.11 HPLC Purification and Quality Control
When necessary, bulk sample purification was performed using a semi-preparative Proteo
column with a flow rate of 5.0 mL/min. Sample purification for in vitro studies was performed
on an analytical Proteo column with a flow rate of 1.5 mL/min. For labeled 177/natIn-conjugates 0
and 1, an initial gradient of 80 % A : 20 % B linearly decreased to 70 % A : 30 % B over a 15
minute time period. For 177/natLu-conjugates 2 and 3, an initial gradient of 75 % A : 25 % B linearly
decreased to 65 % A : 35 % B over a 15 minute time period. At the end of the run time for all
HPLC experiments, the column was flushed with the gradient 5 % A : 95 % B and re-equilibrated
to the starting gradient.
4.2.12 Radiochemical Stability Studies
Twenty five µg samples of

177

Lu-0-3 were mixed with 74 MBq of

177

LuCl3 in an ammonium

acetate buffer (0.5 M, 120 μL, pH 5.5). The mixture was heated at 90 °C for 40 min and
subsequently heated for an additional 5 min in the presence of 4-5 mg CoCl2. The resulting
radioconjugates were peak purified using RP-HPLC and concentrated using a C18 extraction disk
with ethanol/sterile PBS (6:4, 200 μL). The ethanol was evaporated using nitrogen gas and the
resulting solutions were diluted with A: PBS, B: Ascorbic acid in 0.9% sodium chloride solution
(final ascorbic acid concentration: 40mg/ml), C: Selenomethionine (Se-Met) in buffer B (final SeMet concentration: 0.2mg/ml) yielding a final radio-concentration of 74 MBq/ml (2 mCi/ml). The
purity of desired radioconjugates was determined by HPLC at 24, 48 and 72 h.
4.2.13 Partition Coefficient
Partition coefficient was determined for each 177Lu-labeled conjugates. In a microcentrifuge
tube, 0.5mL of 1-octanol was added to 0.5 mL phosphate-buffered saline (pH 7.4) containing the
radiolabeled peptide (500,000 cpm). The solution was vigorously stirred for 2 min at room
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temperature and subsequently centrifuged (100g, 5 min) to yield two immiscible layers. Aliquots
of 100 µL were taken from each layer and the radioactivity of each was quantified by a γcounter. Statistical analysis using the unpaired two-tailed Student’s t test was performed to
compare the logD values. P values < 0.05 were considered statistically signiﬁcant.
4.2.14 In Vitro Competitive Cell-Binding Studies
The half maximum inhibitory concentration (IC50) of the

nat

Lu conjugates were determined

by competitive displacement cell-binding assays using PC-3 cells. natLu-conjugates were used as
substitutes for the corresponding

177

Lu-radioconjugates. Briefly, PC-3 cells (~3×104) were

suspended in RPMI 1640 media (pH 7.4, 4.8 mg/mL HEPES, and 2 mg/mL BSA) and incubated at
4°C for 40 min in the presence of radiolabeled [125I-Tyr4]-Bombesin and various concentrations
of the

nat

Lu-0-3. At the end of the incubation period, the cells were centrifuged, aspirated and

washed with media a total of three times. The cell associated activity was measured using a γcounter and the IC50 values determined by nonlinear regression using the one-binding site
model of Graphpad PRISM 5 (U.S.).
4.2.15 Efflux Studies at Different Oxygen Concentrations
Efflux studies were carried out under atmospheres that contain 5% CO2 and 0.2, 1.0, 2.5, 5
and 21% O2 (21% O2 represents atmospheric oxygen concentrations). PC-3 cells were incubated
in six-well plates (0.5 × 106 / well) in a hypoxic chamber overnight in RPMI 1640 media (pH 7.4,
4.8 mg/mL HEPES, and 2 mg/mL BSA). On the day of the experiment, the medium was removed,
and the cells were washed with medium and incubated for 2 h under different oxygen
concentrations. Cells were incubated for an additional 2 h at 37°C in the presence of 100,000
cpm of each 177Lu-radioconjugate. Upon completion of the incubation at time points 0, 2, 4, and
8 h, the media was harvested to quantitate the amount of effluxed ligand. Surface bound
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radioactivity was collected by washing the cells twice with an acid wash (50 mM glycine-HCl/0.1
M NaCl buffer, pH 2.8). The cells were then lysed at 37°C using a 0.5 % aqueous SDS solution and
the lysates were collected as internalized ligand. The radioactivity of the effluxed, surface bound
and internalized fractions for each radioconjugate at each oxygen concentration was
determined using a γ-counter. Statistical analyses were performed by multiple t-test with HolmSidak correction using Graphpad PRISM 5 (U.S.). A P value of less than 0.05 was considered
statistically significant.
4.2.16 Efflux Study under Various O2 Concentrations
In this experiment, normoxic and hypoxic PC-3 cells were prepared as outlined in the efflux
studies above. PC-3 cells were incubated for 2 h at 37°C in the presence of 100,000 cpm of each
177

Lu-radioconjugate under hypoxic condition (94.9% N2, 0.1% O2, 5% CO2). Upon completion of

the incubation, the 6 well plates were transferred to a normal CO2 incubator. At 2, 4 and 8 h
time points, effluxed, surface bound and internalized radioactivity was measured using the
procedure stated above.
4.3 RESULTS
4.3.1 Synthesis and Radiolabeling
In this study, we targeted the synthesis of four conjugates, each with increasing numbers of
2-nitroimidazoles. In our initial synthetic design, all conjugates were to be synthesized by SPPS
techniques to yield the precursors (designated with an astericks (i.e., 1*)) which would be later
conjugated to 2-nitroimidazole acetic acid (2-NIAA) post-assembly. Note that conjugate 0, which
lacks 2-nitroimidazoles, is our experimental control and did not undergo 2-NIAA coupling. The
desired peptides were easily synthesized by standard SPPS chemistry. Conjugate 0 and
precursors 1*, 2* and 3* were purified by RP-HPLC and isolated with yields of 26.6, 25.7, 20.7
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and 28.2 %, correspondingly. After purification, 2-NIAA was coupled to the Ɛ-amino group of
lysine residue(s) of the precursor conjugates using EDC/NHS in DMF. The coupling yields for
conjugates 1 and 2 after purification by RP-HPLC were 37.8 and 16.9 %, respectively. However,
conjugate 3 gave very poor yields. Despite attempts to improve the yield of 3 by optimizing
concentrations of reactants and the coupling agent, as well as the exploration of other coupling
agents (i.e., HBTU), isolated yields of 3 were never more that 1%.
As a result of this difficulty, an alternative strategy was pursued for the synthesis of
conjugate 3. Instead of a post-conjugation strategy for introducing the 2-NIAA, we set out to
synthesis a 2-NIAA derivative of the Fmoc-D-Lys-OH amino acid, compound III, which could be
employed to directly synthesize conjugate 3 by SPPS. The synthetic scheme is given in Figure 4.2.
Fmoc-D-lysine hydrochloride was reacted with trimethylsilyl chloride to yield compound I, a
methyl ester derivative of Fmoc-D-lysine, in near quantitative yield as determined by LC/MS.
Using EDC/NHS coupling chemistry, 2-NIAA was effectively conjugated to compound I with an
overall yield of 87.4 %. Compound II was crystallographically characterized by x-ray diffraction
studies and is depicted in Figure 4.3. Conversion of compound II to the acid derivative
(compound III) was achieved by hydrolysis using hydrochloric acid. The progress of the reaction
was monitored using LC-MS. The final product was extracted by methanol to give a yield of
37.4%. With compound III in hand, conjugate 3 was directly synthesized by SPPS with a yield of
23.9% after chromatographic purification. The RP-HPLC retention times and mass spectrometric
identification of the conjugates and precursors are listed in Table 4.1.
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Figure 4.2 Synthesis of Fmoc-D-lysine 2NIAA (compound III)
Reagents and conditions: (a) TMSCl, methanol, rt, overnight, 98%; (b) EDC, NHS, rt, overnight;
67%; (c) HCl, rt.
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Figure 4.3 X-ray crystal structure of Compound II
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0
1*
2*

1
2
3
Lu-0

Lu-1

Lu-2
Lu-3

Analogue

C125H187N43O41S

C109H167N35O37S

C92H141N29O27S

C94H158N26O28S

C88H144N24O30S

C85H137N23O31S

2179.9

2978.4

2590.2

2202

2131.1

2049

2008

Calc’d

2375.1

2181.3

2979.7

2591.3

2203.4

2132.6

2050.5

2009.3

Found
a
(m/z,[M +H]+)

7.28

12.2

8.65

5.28

6.65

10.45

12.17

6.33

8.67

RP-HPLC Retention
Time /min

22.1 ± 1.2

10.9 ± 1.4

6.8 ± 1.2

1.0 ± 1.7

15.1 ± 1.3

13.6 ± 1.5

13.1 ± 1.2

-

-

9.8 ± 1.7

IC50/nM

-2.02 ± 0.05

-2.10 ± 0.05

-2.25 ± 0.09

-2.24 ± 0.07

-

-

-

-

-

-

LogD
c
(pH=7.4)

MW

C85H134 LuN23O31S

2374

2763.8

5.4

174

174

Values represent mean ± SEM (n=6) c Values represent mean ± SD (n=3)

b

C93H144 LuN27O33S

2762.1

3151.4

174

C109H164 LuN35O37S

3150.3

174

b

C125H184 LuN43O41S

Molecular Formula

Table 4.1 Mass spectrometric and RP-HPLC characterization of conjugates

DOTA-(D)S-(D)S-(D)S-(D)S(D)S-PEG–BBN(7-14) NH2
DOTA-(D)K-(D)S-(D)S-(D)S(D)S-PEG–BBN(7-14) NH2
DOTA-(D)K-(D)K-(D)K(D)S(D)S-PEG–BBN(7-14)
NH2
DOTA [(D)K (2-NIAA)-(D)S(D)S-(D)S-(D)S-PEG]–BBN(714) NH2
DOTA [(D)K (2-NIAA)*3-(D)S(D)S-PEG]BBN(7-14) NH2
DOTA [(D)K (2-NIAA)*5-PEG]
–BBN(7-14) NH2
Lu-DOTA-(D)S-(D)S-(D)S(D)S-(D)S-PEG–BBN(7-14)
NH2
Lu-DOTA [(D)K (2-NIAA)(D)S-(D)S-(D)S-(D)S-PEG]–
BBN(7-14) NH2
Lu-DOTA [(D)K (2-NIAA)*3(D)S-(D)S-PEG]BBN(7-14)
NH2
Lu-DOTA [(D)K (2-NIAA)*5PEG] –BBN(7-14) NH2

For convenient mass spectra analysis 177Lu was replaced by natLu
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Labeling and purification of the conjugates with
nearly identical conditions.

nat

Lu and

177

Lu were carried out under

177/nat

LuCl3 was incubated with the conjugates, 0 - 3, in a 0.1 M

ammonium acetate buffer (pH 5.5) at 90°C for 40 min. Purification of the

177/nat

Lu-conjugates

was accomplished by RP-HPLC and solid phase extraction on a C18 column with typically ≥ 90%
recovery. Prior to in vitro analysis, purity of each conjugate was determined by RP-HPLC and
found to have ≥ 95% chemical purity. Radiolabeling yields for 177Lu-0, 177Lu-1, 177Lu-2 and 177Lu-3
were 90.5, 74.2, 79.6 and 77.3 %, correspondingly.
4.3.2 Partition Coefficient and Radiochemical Stability
Partition coefficient of the radiolabeled peptides was determined by the shake flask method
and the log D values are given in Table 4.1. The partition ratio of 177Lu-0-3 radioconjugates under
physiological condition (pH = 7.4) were 0.006, 0.005, 0.007 and 0.009, respectively, indicating
highly hydrophilic peptides. Slightly decreased hydrophilicity was observed with increasing
number of incorporated 2-nitroimidazoles.
Previous studies demonstrated a significant increase in radiolytic degradation with
increasing numbers of incorporated 2-NIAA into the structure of the peptide. To combat this
degradation, we investigated the efficacy of known radiostabilizers, ascorbic acid and
selenomethionine, to increase the stability of the modified BB2r-targeted agents. Two groups of
potential stabilizers and control buffers were tested. Figure 4.4 shows the percentage of desired
radioconjugates stored at 4°C for 24, 48 and 72 h in the presence of different stabilizing agents.
Of the tested reducing agents, the free radical scavenger Se-Met was the most effective
radiostabilizer for all 177Lu-conjugates. Over 72 h at 4°C, 5.3, 7.5 15.8 and 30.1% were radiolysed
in the presence of Se-Met for

177

Lu-0-3 whereas only 60.1, 44.9, 50.3 and 15.9% of desired

radioconjugates remained when using PBS. Increased radiolytic rate was observed to be
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associated with increasing numbers of incorporated 2-NIAA.

177

Lu-4 exhibited the highest

radiolytic rate with 30% radiolysed at 72 h even with the presence of Se-Met (radio-HPLC
chromatography shown in figure 4.5).
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Figure 4.4 Radiochemical stability studies
Radiochemical stability studies depicted as % of desired radioconjugates as a function of time.
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177Lu-2
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Figure 4.4 (continued) Radiochemical stability studies depicted as % of desired
radioconjugates as a function of time.
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Figure 4.5 Radio-stability studies of 177Lu-4
Radio-stability studies of 177Lu-4 as determined by radio-HPLC at 24, 48, and 72 h postincubation.
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4.3.3 In Vitro Competitive Cell-Binding Studies
A competitive displacement binding assay (IC50) of BBN(7-14)NH2 was determined in GRPrpositive PC-3 cells using [125I-(Tyr4)-BBN] radioligands. For both unlabeled and
conjugates,

nat

Lu-labeled

nat

Lu-0 demonstrated the highest affinity binding (1nM) to the BB2r. The binding

affinity slightly decreased with more 2-nitroimidazoles incorporated into the structure. The IC50
values of natLu-0-3 were 1.0, 6.8, 10.9 and 22.1 nM, respectively. IC50 values are summarized In
Table 4.1.
4.3.4 Efflux Studies
Efflux studies were performed under various oxygen environments to determine the effect
oxygen concentration has on the rate at which radioconjugates 177Lu-0-3 are effluxed from PC-3
cells. In these studies, 177Lu-0, is the control and was used to compare the relative effectiveness
of the hypoxia trapping conjugates (177Lu-1-3). The percentile efflux rates for
depicted in Figure 4.6.

177

Lu-1-3 are
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% radioactivity effluxed
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Figure 4.6 Efflux assays for the 111In-radioconjugates in PC-3 cells
Efflux assays depicted as percentage of initial internalized activity for the 111In-radioconjugates
in PC-3 cells at different oxygen concentrations. Values are mean ± SD (n=5).
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Figure 4.5 (continued) Efflux assays depicted as percentage of initial internalized activity for
the 111In-radioconjugates in PC-3 cells at different oxygen concentrations. Values are mean ±
SD (n=5).
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The efflux rates for the control

177

Lu-0 under various oxygen concentrations were similar

over the timepoints investigated. After 2 h, approximately 40 % of the originally internalized
radioactivity for

177

Lu-0 was effluxed. By 8 h, the amount of effluxed radioactivity had reached

approximately 60%. Overall for the control,

177

Lu-0, the efflux of radioactivity from PC-3 cells

over the various oxygen concentrations was found to be statistically identical between groups
and thus was independent of oxygen concentration. For

177

Lu-1-3, the radioconjugates

demonstrated efflux rates that were highly dependent on oxygen concentration. At the 2 h time
point, the efflux of radioactivity averaged 23 to 45% for

177

Lu-1-3 under 0.2, 1, 2.5, 5 and 21%

O2, correspondingly. With exception of the studies carried out at 2.5% O2, the efflux of
radioactivity from the PC-3 cells largely plateaued by the 4 h time point. Efflux maxima for 177Lu1-3 were observed at the 8 h time point for all O2 concentrations investigated. From lower to
higher pO2, approximately 28, 39, 54, 60 and 69% of radioconjugates were effluxed. Overall 2nitroimidazole containing radioconjugates

177

lower pO2. Over the timepoints investigated,

Lu-1-3 showed a significantly higher retention at
177

Lu-1-3 demonstrated a linear correlation with

oxygen concentrations.
In order to gauge the impact of O2 deprivation on the efflux rate, we performed a series of
studies in which the 177Lu-0-3 conjugates were allowed to internalize in PC-3 cells under 0.2% O2
conditions for 2 h. After which time, the efflux of the radioactivity from the cells was
investigated under an oxygen-rich environment (i.e., 21%). The results of these studies for 177Lu0-3 are shown in Figure 4.7.
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Figure 4.7 Efflux study under “0.2 to 21%” O2 concentration
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Figure 4.6 (continued) Efflux study under “0.2 to 21%” O2 concentration
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The control 177Lu-0 showed a similar efflux pattern as in efflux studies. The percentage of
efflux radioactivity was 64% at 8 h which is close to 67% of efflux at 21% O 2. However,
conjugates 177Lu-1-3 showed significantly lower efflux rates when pre-incubated under 0.2% O2.
The conjugate 177Lu-1-3 showed 41, 58 and 56% of effluxed radioactivity compared with 68, 68
and 71% of effluxed radioactivity under 21% O2 at 8 h timepoint.
4.4 DISCUSSION
The success or failure of a receptor-targeted diagnostic and radiotherapeutic
radiopharmaceutical for clinical application depends on many factors. These factors range from
the basic chemical properties of the drug (e.g., chemical stability and radionuclide emission
properties) all the way to commercial practicalities (e.g., cost and availability). While all of these
various aspects are important, the achievable target-to-non-target ratios can be viewed as one
of the most vital indicators of a drug’s potential success. Therefore, the development of
approaches to increase the target-to-non-target ratios of receptor-targeted agents would be of
significant interest to the radiopharmaceutical research community. Our laboratory is currently
pursuing this avenue of research using the 2-nitroimidazoles as a hypoxia-selective trapping
agent to selectively increase the residence time of the receptor-targeted radiotracer in hypoxic
cancers thus yielding higher tumor-to-non-target ratios.
Recently, we have reported the development and evaluation of BB2r-targeted agents with
2-nitroimidazoles incorporated into the structure of the peptide [165, 166]. These studies have
shown that these “hypoxia-enhanced” BB2r-targeted agents demonstrate significantly higher
retention in hypoxic relative to normoxic prostate cancer cells. In addition, we found an
increased association of the internalized radiotracer with intracellular proteins. Taken together,
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these finding, while anecdotal, are consistent with the known trapping mechanisms of 2nitroimidazoles. Furthermore, our laboratory has previously observed a substantial increase in
radiolytic degradation with increasing number of incorporated 2-nitroimidazoles. In this report,
we describe the synthesis of a new set of hypoxia-enhanced BB2r-targeted agents with 1, 3 and
5 2-nitroimidazole moieties incorporated into the structure of the peptide. With these agents in
hand, we evaluated the radiolytic stability of these agents as well as examined the effect oxygen
concentration has on cellular retention.
Initially, the synthesis of conjugates 1-3 was pursued by first assembling the BB2r-targeted
peptide by SPPS and subsequently coupling the 2-nitroimidazoles to the construct. Using this
approach, we found that yields of the conjugates decreased with increasing numbers of 2nitroimidazoles per peptide. While this approach was successful for obtaining adequate
quantities of 1 and 2, conjugate 3 gave relatively very poor yields (≤ 1 %) by this route.
Evaluation of the reaction mixture of 3 by LC-MS revealed numerous structural isomers with
incomplete 2-nitroimidazole conjugation. Attempts to increase the yield of 3 by increasing the
ratio of 2-NIAA to peptide, performing the coupling reaction with higher concentrations of EDC
or increasing the reaction time were unsuccessful. Moreover, the exploration of other coupling
agents (e.g., HBTU) did not lead to improvements in the synthetic yield. Overall, these results
suggest to us that steric inhibition may be a significant factor limiting conversion to conjugate 3.
As a consequence of our inability to synthesize 3 by post-modification, we alternatively
chose to synthesize the conjugate by a pre-modification approach. Using the scheme in Figure
4.1, the Fmoc-D-lysine was conjugated to the 2-NIAA prior to SPPS assembly. With the altered
amino acid in hand, we assembled conjugate 3 by SPPS achieving an isolated yield of 23.9 %.
This yield is consistent with those attained for conjugate 0 (26.6 %) and the precursor
conjugates 1*-3* (20.7 - 28.2 %). This result suggests that the increased steric bulk of compound
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III, relative to the unaltered Fmoc-Lysine, did not significantly influence the coupling efficiency of
the amino acid during SPPS. Given the overall poor yields by the post-modification approach,
particularly when conjugating more than one 2-NIAA, the pre-modification approach appears to
be the desirable method for incorporating this agent into the structure of targeted peptides.
The conjugates were radiolabeled with 177LuCl3 to obtain 177Lu-0-3 with good radiochemical
yields (74.2 - 90.5 %). All of the radioconjugates synthesized were found to have hydrophilic
distribution coefficients (log D = -2.25 ± 0.07 - -2.02 ± 0.05) at physiological pH. As more 2nitroimidazoles were added to the peptide the radioconjugates exhibited increased
hydrophobicity. This observation is likely due to the fact that 2-nitroimidazole (pKa ~ 9) remains
largely uncharged under physiological conditions. The incremental incorporation of the
uncharged 2-nitroimidazole ring systems is increasing the hydrophobicity of 177Lu-1-3. However,
even with some small increases in hydrophobicity being observed, all of the radioconjugates
synthesized have distribution coefficient that are low enough to discount passive diffusion as a
significant mechanism of entry across cellular membranes. Therefore, cellular uptake of 177Lu-03, as with most reported BB2r-targeted agents, is expected to be primarily attributed to
receptor-mediated endocytosis. This is in contrast with most hypoxia imaging agents based on
2-nitroimidazole which are relatively hydrophobic and rely on passive diffusion as the primary
route of distribution. This mechanism of cellular uptake for the hypoxia-enhanced BB2r-targeted
agents is important for tissue specificity. The dependence on the radioconjugates on receptor
mediated uptake, instead of passive diffusion, dictates that the agents will be primarily taken up
into BB2r-positive tissues.
It is well established that ionizing radiation (α2+ and β- particles) can directly or indirectly,
through the generation of solvated electrons and free radicals species, degrade peptides and
proteins [167]. Previous studies showed that

111

In-labeled bombesin conjugates were very
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radiosensitive and the radiolytic rate was associated with the amount of incorporated 2nitroimidazoles. Without radiostabilizers, degradation occurred both during radiolabeling and
after HPLC purification. Se-Met has been widely used to protect against radiation- and chemicalinduced carcinogenesis in both preclinical and clinical studies. It has been previously
demonstrated that Se-Met is very effective in protecting

177

Lu-labeled bombesin conjugates

from radiolytic degradation when combined with ascorbic acid. In this study, the Se-Met
containing AA buffer showed the best stabilizing capability.
Investigations into the BB2r-avidity of the synthesized conjugates and radioconjugates
revealed that a small incremental decrease in binding affinity was observed as more 2-NIAAs
were added to the peptide, particularly in the case of the radioconjugates. However, the
inclusion of the 2-NIAA moieties did not seem to substantially impact the overall affinity of the
conjugates or radioconjugates studied. Moreover, internalization studies of

177

Lu-0-3 revealed

that all of the radioconjugates had statistically identical percentages of cellular accumulation
after 2 h of incubation, demonstrating that the inclusion of 2-NIAA did not inhibit the ability of
the radioconjugates to activate the BB2r-mediated endocytotic pathway.
The efflux profiles for conjugates

177

Lu-0-3 in PC-3 cells under 0.2, 1, 2.5, 5 and 21% O2

concentration over 8 h are displayed in Figure 4.5. At all examined time points, the control 177Lu0 showed similar efflux pattern at different O2 concentrations. At end of the studies, 61.19±
6.59, 63.07±3.23, 63.42±1.57, 62.32±1.64 and 67.32± 2.33 % radioactivities were effluxed under
0.2, 1, 2.5, 5 and 21% O2 concentration respectively. Overall efflux rate of

177

Lu-0 was

independent of pO2 in this study.
177

Lu-1-3 shows lower efflux rates at 0.2% O2. At 8 h radioactivity effluxed were 28.41±2.32,

27.98±1.55, and 29.58 ± % respectively. Under 1, 2.5 and 5 % pO2

177

Lu-1 exhibits steadily
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increased oxygen dependent efflux rates, but it was substantially lower than the trend observed
in normoxic cells (21% O2). The conjugate

177

Lu-2 demonstrates 42.91± 3.88 % cellular efflux

under 21% O2 at 2 h which increased to 68.51 ± 2.94 % at 8 h. However, at 0.2% O 2, only 27.98
±1.55 % was effluxed at 8 h. Furthermore at 1, 2.5 and 5 % O2 concentrations,

177

Lu-2

radioactivity efflux rates were increased to 36.90±0.97, 53.20 ±0.75 and 59.85 ±1.62 %
correspondingly at 8h.
At the beginning of experiment at 2 h

177

Lu-3 exhibited significantly higher cellular efflux

which is 55.36 ± 2.18 % at 21% O2 compared with

177

Lu-1and

177

Lu-2. Although by 8 h,

177

Lu-3

exhibited an efflux rate of 71.09 ±2.81% matching with the radioconjugates 177Lu-1 and 177Lu-2.
Furthermore at 1, 2.5 and 5 % O2, the percentage of effluxed

177

Lu-3 were 42.07±1.48,

58.10±3.18 and 63.80±1.75 respectively. Interestingly, when the partial oxygen pressure is
above 5%, the percentage of effluxed radioactivities were found to be significantly higher
compared with 177Lu-1-2 (p < 0.05 to 0.001).
Overall in this experiment, lower efflux rates for the radioconjugates 177Lu-1-3 was observed
when the cells are exposed at 5 % O2 or less. Furthermore, the retention of the 177Lu 1-3 in the
cells under 0.2% oxygen was twice that of the cells under 2.5 % oxygen indicating the hypoxia
trapping efficiency of these designed radio-conjugates is dependent on the O2 concentrations.
In another set of experiment where PC-3 cells were pre-incubated with

177

Lu-0-3 for 2 h

under hypoxic (0.2 % O2) conditions, followed by measuring efflux rate over normoxic (21 % O2)
at 2, 4 and 8 h. At 2 h, the cellular efflux of

177

Lu-0 was 35. 48 ±0.83 at 0.2 - 21 % O2 which is

consistent with what has previously been observed at 0.2 and 21 % O2 concentrations. With the
introduction of increasing numbers of 2-nitroimidazole moieties to the conjugates, that is,
177

Lu1-3, the reflux rate was decreased remarkably from 35.17±2.84, 43.01±1.76, 46.21±4.33
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respectively which is significantly lower than the efflux profile observed at 21 % O2
concentrations. The same trend was noted for timepoints at 4 and 8 h. The efflux proﬁle of
177

Lu1-3 at varying oxygen concentrations 0.2 -21 % O2 were identical, with all three conjugates

displaying their 1.3 -1.5 fold decrease in efflux rate between 21 and 0.2-21 % O2 .This study
indicates that the 2-nitroimidazole derivatives showed lower efflux rates under low O2 levels
compared with 21% O2. Rationale behind this is 2-nitroimidazoles bind irreversibly to
intracellular proteins, which is consistent with the known trapping mechanism of 2nitroimidazole. These results indicate that retention of these compounds in hypoxic cells were
oxygen concentration dependent.
4.5 CONCLUSION
In conclusion, we have synthesized and evaluated three BB2r-targeted radioconjugates that
have 2-nitroimidazole hypoxia trapping moieties conjugated to the linking group of the peptide,
for the purpose of enhancing retention in hypoxic cancers. Three hypoxia trapping enhanced
BB2r-targeted radioconjugates with mini-PEG linkers were synthesized. All conjugates
demonstrated hydrophilic nature under physiological conditions. The synthesized

177

Lu-0-3

bombesin conjugates exhibited nanomolar binding affinities towards the BB2r in the PC-3
prostate cancer cell line. This study signifies the use of selenomethionine and ascorbic acid in
combination can efficiently reduce the radiolytic rate associated with 2-nitroimidazole. In
addition, in vitro efflux studies under different oxygen concentrations demonstrated that these
conjugates were preferentially retained in hypoxic cancer cells which is an oxygen dependent
process. The work carried out suggests a potential new avenue to significantly increase efficacy
of diagnostic and therapeutic BB2r-targeted drugs in a variety of cancers.
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Chapter 5 DISCUSSION
Among many techniques for oncological imaging, nuclear medicine techniques are of
growing importance. Compared to MRI and optical imaging, nuclear imaging has good sensitivity
for deep tissue due to continuously generated signals by the decay process of radionuclides.
Tremendous effort has been made for development of radiolabeled antibodies and their
fragments during the past 40 years [168]. Although promising results have been published, the
radiolabeled antibodies have disadvantages, mainly associated with their high molecular weight,
such as sequestration by reticuloendothelial cells and long elimination half-life. Low-molecularweight based radiotracers, such as receptor-targeted regulatory peptides, are rapidly taken up
in the target tissues and usually have fast plasma clearance through renal excretion, which leads
to high tumor-to-non-target ratios quickly after administration. Unfortunately, one of the major
challenges, especially for therapeutic application, of many low-molecular-weight, receptortargeted peptides is the short tumor residence times due to intrinsically high diffusion and efflux
rates. After receptor mediated uptake of radiotracers, a rapid tumor washout is often observed
which substantially reduces the theranostic efficacy and clinical potential.
We seek to address this problem by incorporating hypoxiatrapping agents into the peptidic
radiotracer, which is expected to selectively increase the residence time in hypoxic tumor
tissues. The main idea behind this approach is depicted in Figure 5.1. After receptor mediated
uptake of radiotracers, the 2-nitroimidazole trapping moieties will become activated and
irreversibly bind to intracellular nucleophiles, such as cytoplasmic proteins. The expectation of
this approach was that the binding to the intracellular macromolecules will substantially
increase the retention time of radiolabeled peptides in hypoxic tumor tissues leading to an
increase in diagnostic/therapeutic efficacy and clinical potential.
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Figure 5.1 Trapping mechanism of hypoxia enhanced 111In-BB2r-targeted conjugates
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As the first attempt of development of the hypoxia trapping enhanced system, we chose the
widely investigated bombesin(7-14)NH2 as the targeting peptide and 2-nitroimidazole as the
hypoxia trapping agent. Bombesin(7-14)NH2 peptides are able to agonistically bind to the BB2
receptor that is overexpressed on a variety of cancers with high (typically nanomolar) affinity.
Derivatives of 2-nitroimidazole have been actively studied as hypoxia targeted agents that are
able to quantify the hypoxic burden present in tumors. A total of four hypoxia trappingenhanced bombesin conjugates were synthesized in chapter 2. Receptor saturation studies
reveal that the BB2r expression is independent of oxygen level. In vitro internalization assays
revealed significantly improved residence time of 2-nitroimidazole containing conjugates in PC-3
hypoxic cells. However, our studies indicate that incorporation of the 2-nitroimidazole moieties
close to the pharmacophore impairs the BB2r binding affinity of these radioconjugates.
Additionally, we found significantly higher protein association of 2-nitroimidazole incorporated
conjugates under hypoxic conditions which suggests the trapping mechanism is at least partially
associated with the 2-nitroimidazole moiety.
To eliminate any steric interference which the 2- nitroimidazoles might impose on the BB2rtargeting vector, a new series of conjugates with an extended linker (8-Aoc) incorporated
between the 2-nitroimidazole-amino acid residue and the pharmacophore were synthesized in
chapter 3. Based on the results of competitive binding studies, the incorporation of an extended
linker has eliminated the detrimental effect of the 2-NIAA side chain on pharmacophore binding.
In vitro studies demonstrated substantially lower efflux rates and higher protein association for
2-nitroimidazole containing conjugates under hypoxic conditions. As a result of the promising in
vitro performance, we carried out the first in vivo investigation of these radioconjuagtes in a PC3 xenograft mouse model. Significant tumor retention enhancement was observed at 72 h post
injection for radioconjugates 111In-2 and 111In-4. Up to 20% higher tumor retention for 111In-4 was
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observed relative to the control 111In-1. All radioconjugates exhibited substantial accumulation of
radioactivity in the tumor site based on the MicroSPET/CT images. It is interesting to note that
the unusual high radiolytic rate and kidney retention seem to be associated with the
incorporated 2-nitroimidazoles. Further studies are needed to elucidate the underlying
molecular mechanisms.
To address the high kidney retention issue, a miniPEG linker was adopted due to the fact that
the hydrophilic linker can increase the clearance rate from non-target organs. Stabilizing buffer
containing selenomethionine was introduced to protect against the radiolysis of the targeting
peptides. Considering the exhibited long term tumor retention in chapter 2, Lutetium-177 was
utilized to examine the therapeutic potential of these radioconjugates. A total of four hypoxia
enhanced bombesin conjugates were synthesized including all the modifications mentioned
above in Chapter 4. Storage buffer containing selenomethionine was demonstrated to be very
effective in protecting these

177

Lu-labeled bombesin conjugates from radiolytic degradation

when combined with ascorbic acid. Efflux studies were performed under various pO2 (0.2, 1, 2.5,
5 and O2) to evaluate the efficacy of the hypoxia trapping moieties to enhance retention in
hypoxic PC-3 cells. Overall in this experiment, lower efflux rates for the radioconjugates 177Lu-1-3
were observed following a pO2-dependent manner, while the efflux rate of the control was
unchanged at various pO2.
In summary, a hypoxia trapping enhanced BB2r-targeted radiopeptide system was
established. These radioconjugates exhibited significantly higher retention in hypoxic PC-3 tumor
cells compared to the control. Strong cellular protein association was observed for all hypoxia trapping enhanced conjugates which suggest the important role of 2-nitroimidazole for this
enhancement. In vivo biodistribution studies revealed great long term tumor retention
improvement, which suggests the therapeutic potential of the developed system.
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Future Studies
1. Cell trafficking studies using confocal microscopy
As discussed earlier, the hypoxia trapping mechanism of 2-nitroimidazole is that it can bind
to macromolecules such as protein in the cytoplasm compartment. Previous studies
demonstrated that GRP are rapidly internalized into early endosomes and then trafficked and
degraded in the lysosomes [169]. Subcellular localization and quantification of hypoxia trapping
enhanced peptides is therefore needed to investigate a potential peptide recycling route which
may affect the hypoxia trapping efficacy. We have already established the staining protocol for
early endosomes, late endosomes and lysosomes using CellLight® Early Endosomes-GFP,
CellLight® Late Endosomes-RFP, and LysoTracker® Blue DND-22. We have also synthesized
peptide analogs that are labeled with Cy®5 dye. Calculation of colocalization coefficients of
peptides with each organelle is ongoing using the Zen® colocalization analysis module.
2. Colocalization of radioactive signal with tumor hypoxic region
The extent of hypoxia in tumors appears to be strongly associated with the aggressiveness
of the tumor phenotype, therapeutic resistance and patient prognosis [105]. In the clinic, the
development of tumor hypoxia is independent of clinical size, stage, histology, grade and various
patient demographics [170]. The hypoxic burden in tumor xenograft mouse models has been
shown to correlate with tumor size, but it is highly dependent on the cell-line used [151]. It is
therefore very important to quantify the tumor hypoxia burden for the xenograft model to
better interpret the trapping efficiency of our system. We have already developed an immunohistochemistry staining protocol for quantification of tumor hypoxia using pimonidazole. We
have also established an autoradiography method to colocalize the radioactive signal with
pimonidazole staining.
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3. Synthesis of nitrogen mustard based hypoxia trapping agents
It has been previously demonstrated that only a fraction (~10%) of activated nitroimidazoles
can form adducts with protein, partially because of the fast reaction of hydroxylamine
intermediates with advantageous water molecules [131]. Activated nitrogen mustards have
substantially longer lifetimes relative to activated nitroimidazoles, which may offer increased
selectivity and lead to increased retention in hypoxic cells [171, 172]. Several nitrogen mustard
agents such as TH302 and PR-104H are currently being evaluated in several phase II and phase III
clinical trials [173-177]. We have begun to modify TH302 with addition of carbocyclic acid
functionality to facilitate the conjugation to the peptide backbone.
4. Evaluation of the therapeutic efficacy using a patient-derived orthotropic xenograft model
The advantages of using subcutaneous xenograft models are (1) easy to establish; (2) easy to
monitor; (3) convenient to quantify the tumor burden. However, the drug response on a
subcutaneous xenograft model using human cell lines does not often correlate with clinical
activity in human patients [178]. One reason is that the tumor is not orthotopically localized and
specific molecules, such as hormones, which are crucial for development of breast and prostate
cancer, are not expressed. Tremendous efforts have been made to develop techniques of
surgical implantation of patient-derived tumors to the corresponding organ of rodents [179-181].
Strong predictive response values of clinical activity in patients were observed when using
orthotopic xenograft tumor model [182-184]. Due to the fact that BB2r expression is androgendependent, the hypoxia enhanced BB2r-targeted agents will be investigated in a patient-derived
orthotopic xenograft model in the future.
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